US20160145348A1 - Compositions and methods to modify cells for therapeutic objectives - Google Patents

Compositions and methods to modify cells for therapeutic objectives Download PDF

Info

Publication number
US20160145348A1
US20160145348A1 US14/776,661 US201414776661A US2016145348A1 US 20160145348 A1 US20160145348 A1 US 20160145348A1 US 201414776661 A US201414776661 A US 201414776661A US 2016145348 A1 US2016145348 A1 US 2016145348A1
Authority
US
United States
Prior art keywords
antibody
cells
cell
lymphocyte
synthetic nanocarrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/776,661
Other languages
English (en)
Inventor
Matthias Stephan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Priority to US14/776,661 priority Critical patent/US20160145348A1/en
Assigned to FRED HUTCHINSON CANCER RESEARCH CENTER reassignment FRED HUTCHINSON CANCER RESEARCH CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEPHAN, MATTHIAS
Publication of US20160145348A1 publication Critical patent/US20160145348A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A61K47/48561—
    • A61K47/48823—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Definitions

  • compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives.
  • the methods can be practiced in vivo and any cell type that expresses or is associated with a known marker can be targeted for a therapeutic objective by the modified cell.
  • compositions and methods that rapidly and selectively direct cells of the immune system to achieve therapeutic objectives.
  • vaccines are used to prime the immune system to target antigens associated with unwanted cells.
  • the biological processes underlying conventional vaccines can render them ineffective against many unwanted cells based on, among other factors, the time it takes to prime the immune system, the amount or degree to which the natural immune system can be primed against certain unwanted cell types and over time, the depletion of immune system resources.
  • conventional vaccine approaches can be ineffective against cancer cells and cells affected by certain infectious diseases.
  • vaccines can be capable of targeting the immune system to destroy cancer cells in some patients.
  • the immune response using this approach requires months to mature and during this time, cancers can significantly progress and become fatal.
  • conventional vaccines do not provide an adequate method to target and destroy unwanted cancer cells.
  • T-cell transfer therapies are also time and labor-intense and must be personalized for each patient in cell production facilities, which are available only at a few highly specialized cancer centers worldwide. Similar issues are encountered with a number of other unwanted cell types. Thus, additional solutions are needed that allow rapid and selective direction of cells of the immune system to achieve therapeutic objectives
  • compositions and methods that can rapidly and selectively direct cells of the immune system to achieve therapeutic objectives.
  • the compositions and methods modify cells of the immune system, such as T cells or natural killer (NK) cells, to target and destroy unwanted cell types.
  • the compositions and methods modify cells of the immune system, such as monocytes/macrophages, to target and destroy viruses before they infect cells and/or to target bacteria or fungus.
  • the compositions and methods modify cells of the immune system, such as B cells, to produce and release antibodies, such as broadly-neutralizing antibodies.
  • the compositions and methods modify cells of the immune system, such as immunosuppressive regulatory T cells (T REG ) to target and protect, rather than destroy, cell types.
  • T REG immunosuppressive regulatory T cells
  • Compositions and methods disclosed herein can also be used to modify stem cells to achieve therapeutic objectives.
  • the described methods can be practiced in vivo rather than requiring patient-specific isolation and culturing, as is currently required by many cancer treatments.
  • the methods can be practiced in vivo because following administration to a subject, the compositions selectively modify cells of the immune system to achieve selected therapeutic objectives.
  • compositions and methods can be used to target any cell type for which a marker is now or later becomes known.
  • the compositions and methods achieve this benefit by modifying cells of the immune system to express targeting agents for the marker of interest.
  • the cells of the immune system are modified to express targeting agents that bind markers, such as antigens, on unwanted cells. Once bound to an unwanted cell, the immune cells mediate its destruction.
  • the cells of the immune system can be modified to express targeting agents that bind markers expressed by wanted cells or cells in the vicinity of wanted cells. Once bound to a wanted cell or in the vicinity of a wanted cell, the immune cells can mediate protection of the wanted cell.
  • compositions and methods disclosed herein also provide further advantages over the current state of the art.
  • the compositions and methods can selectively destroy unwanted cells leaving healthy tissue undamaged.
  • the compositions can be manufactured on a large scale in a stable form with a long shelf life rendering them compatible with wide distribution and inexpensive administration to large patient populations in outpatient settings (i.e., they provide “off-the-shelf” directed treatments).
  • the compositions can be administered in booster doses to reinforce immune cell targeting.
  • the administered composition can be altered over time as a population of unwanted or wanted cell types (collectively “targets” herein) evolves.
  • the nanocarriers include a polynucleotide encoding a targeting agent.
  • the nanocarrier is taken up by a cell of the immune system, which then expresses the encoded targeting agent.
  • the targeting agent selectively binds a marker on a target, directing the cells of the immune system to the site of the therapeutic objective. If the expressed targeting agent is an unwanted cell-targeting agent (such as an antibody or a receptor for a cancer antigen), once bound, the modified immune cell will mediate the destruction of the unwanted cell. If the expressed targeting agent is a wanted cell-targeting agent (such as a receptor for a marker expressed by a cell undergoing autoimmune attack), once bound, the modified immune cell will mediate the protection of the wanted cell.
  • an unwanted cell-targeting agent such as an antibody or a receptor for a cancer antigen
  • nanocarriers further include lymphocyte-directing agents.
  • Lymphocyte-directing agents can achieve selective uptake of the nanocarriers by cells of interest for a particular therapeutic objective.
  • the lymphocyte-directing agents can include binding domains extending from the surface of the nanocarriers that facilitate uptake by lymphocytes or particular classes of lymphocytes.
  • Nanocarriers can also include lymphocyte-directing agents that achieve selective uptake by more than one cell type.
  • Nanocarriers can also further include one or more of: an endosomal release agent to facilitate release of the polynucleotide from endosomal compartments of the lymphocytes and/or a nuclear localization signal (NLS) to direct the polynucleotide into the nucleus of the lymphocyte for expression, particularly when, for example, the polynucleotide comprises plasmid DNA.
  • an endosomal release agent to facilitate release of the polynucleotide from endosomal compartments of the lymphocytes
  • NLS nuclear localization signal
  • the nanocarriers comprise a porous nanoparticle surrounded by a coating.
  • the polynucleotide and optionally the NLS
  • the optional lymphocyte-directing agent and endosomal release agent can extend from the surface of the coating.
  • FIG. 1 Schematic of described strategy to rapidly and selectively modify immune cells for therapeutic objectives using synthetic nanocarriers.
  • Nanocarriers are loaded with polynucleotides that encode a targeting agent (e.g. tumor- or virus-specific T-cell receptor).
  • a targeting agent e.g. tumor- or virus-specific T-cell receptor.
  • Surface-anchored lymphocyte directing agents e.g. anti-CD3 antibody
  • the nanocarriers Upon infusion into a patient's bloodstream, the nanocarriers transfer the polynucleotide molecules into lymphocytes, which subsequently express the targeting agent on their surface. Lymphocytes then recognize and lyse cells of interest (e.g. cancerous or virus-infected cells).
  • FIG. 2 (A) Schematic representation of the protocell nanoparticle used in studies described herein. (B) A representative TEM image of a protocell nanoparticle.
  • FIG. 3 Schematic representation of minicircle DNA construct used in studies described herein. Structure of the P28z minicircle.
  • PSMA prostate-specific membrane antigen
  • the prostate-specific membrane antigen (PSMA)-targeting chimeric antigen receptor P28z is expressed under the control of the T-cell-specific CD3-delta promoter.
  • FIG. 4 Redirecting T-cell specificity toward prostate tumor via nanoparticle-mediated gene transfer.
  • PSMA Prostate-Specific Membrane Antigen
  • B Flow cytometric measurement of surface P28z expression on mouse effector T cells 30 hours after incubation with “empty” (left panel) or P28z minicircle-loaded (right panel) protocell nanoparticles.
  • C 51Cr release assay of T cells 30 h after nanoparticle transfection targeting PSMA-positive TRAMP prostate tumor cells.
  • D Light microscope images of nanoparticle-transfected T cells co-cultured on a TRAMP prostate tumor cell monolayer.
  • E Flow cytometric measurement of protocell binding to circulating host T cells 6 hours after intravenous injection of 1 ⁇ 10 11 fluorescently tagged nanoparticles.
  • FIG. 5 Repeated injections of nanocarriers loaded DNA encoding the P28z chimeric antigen receptor brings about T-cell mediated regression of prostate tumor in mice.
  • Luciferase tagged TRAMP-PSMA prostate tumor cells were transplanted into the dorsal lobe of the prostate gland of C57BL/6 mice. Two weeks later (Day 0), mice were treated with five high-dose bolus injections of 1 ⁇ 10 12 CD3-targeting nanoparticles carrying P28z-encoding transgenes (Day 0, Day 2, Day 4, Day 6, and Day 8). Control mice received no nanoparticles.
  • A Sequential bioluminescence imaging of Firefly luciferase-expressing TRAMP-PSMA tumors.
  • FIG. 6 Schematic representation of minicircle DNA constructs.
  • A Structure of the P28z minicircle.
  • the prostate-specific membrane antigen (PSMA)-targeting chimeric antigen receptor P28z is expressed under the control of the T-cell specific CD3-delta promoter.
  • B A scaffold/matrix attachment region (S/MAR) is shown upstream of the poly-A signal to allow sustained episomal replication.
  • C Alternatively, the gene expression cassette can be flanked by the piggyBac inverted terminal repeats.
  • the piggyBac transposon is a mobile genetic element that efficiently transposes between vector and chromosome via a “cut and paste” mechanism. This integration event is mediated by piggyBac transposase. Therefore, in piggyBac transposon studies, a plasmid encoding the hyperactive form of piggyBac transposase iPB7 will be co-encapsulated into protocell nanoparticles.
  • compositions and methods that can rapidly and selectively direct cells within the body to achieve therapeutic objectives.
  • the compositions and methods modify cells of the immune system, such as T-cells or NK cells, to target and destroy unwanted cell types.
  • the compositions and methods modify cells of the immune system, such as monocytes/macrophages to target and destroy viruses before they infect cells and/or bacterial or fungal cells.
  • the compositions and methods modify cells of the immune system, such as B cells, to produce and release antibodies, such as broadly-neutralizing antibodies.
  • the compositions and methods modify cells of the immune system, such as immunosuppressive T REG cells to target and protect cell types from, for example, autoimmune attack.
  • Compositions and methods disclosed herein can also be used to modify stem cells to achieve therapeutic objectives.
  • the described methods can be practiced in vivo rather than requiring patient-specific isolation and culturing, as is currently required by many treatments.
  • the methods can be practiced in vivo because following administration to a subject, the compositions selectively modify cells of interest to achieve the therapeutic objective.
  • one of the primary goals of clinical health research is to develop compositions and methods to rapidly and selectively direct the immune system to destroy unwanted cells.
  • vaccines are used to prime the immune system to target antigens associated with unwanted cells.
  • the biological processes underlying conventional vaccines can render them ineffective against many unwanted cells based on, among other factors, the time it takes to prime the immune system, the amount or degree to which the natural immune system can be primed against certain unwanted cell types and over time, the depletion of immune system resources.
  • compositions and methods that can rapidly modify cells of the immune system to target and destroy unwanted cell types.
  • the methods can be practiced in vivo rather than requiring patient-specific isolation and culturing, as is currently required by many cancer treatments.
  • the methods can be practiced in vivo because following administration to a subject, the compositions selectively modify cells of the immune system to target unwanted cell types.
  • compositions and methods can be used to target any cell type for which a marker is now or later becomes known.
  • the compositions and methods achieve this benefit by modifying cells of the immune system to express targeting agents for the marker expressed by the target or in the vicinity of a target.
  • the cells of the immune system are modified to express targeting agents that bind markers, such as antigens, on unwanted cells. Once bound to an unwanted cell, the immune cells mediate its destruction.
  • cells of the immune system can be modified to express targeting agents that bind markers on or in the vicinity of wanted cells. Once bound to a wanted cell or in the wanted cell's vicinity, the immune cell can mediate its protection.
  • compositions and methods achieve the described benefits by providing nanocarriers that include a polynucleotide encoding a targeting agent.
  • Cells that uptake the nanocarrier will begin to express the polynucleotide, thereby expressing the targeting agent.
  • the targeting agent directs the modified immune cell to the site of the therapeutic objective.
  • a lymphocyte uptakes the nanocarrier and begins to express an unwanted cell targeting agent.
  • the lymphocyte then binds and mediates the destruction of the unwanted cell type.
  • compositions can further include one or more of: an endosomal release agent to facilitate release of the polynucleotide from endosomal compartments of cells of the immune system and/or a nuclear localization signal (NLS) to direct the polynucleotide into the nucleus of the cell for expression if, for example, the polynucleotide includes plasmid DNA.
  • an endosomal release agent to facilitate release of the polynucleotide from endosomal compartments of cells of the immune system
  • NLS nuclear localization signal
  • the nanocarriers comprise a porous nanoparticle surrounded by a coating.
  • the polynucleotide and optionally the NLS
  • the lymphocyte-directing agent and optionally the endosomal release agent
  • lymphocyte-directing agents of the disclosed compositions selectively bind immune cells of interest.
  • the cells are lymphocytes.
  • lymphocyte-directing agents can direct the compositions to any lymphocyte capable of, without limitation, (i) targeting and killing unwanted cells, (ii) targeting unwanted cells for killing by other cell types, (iii) mediating unwanted cell killing; (iv) targeting viruses for destruction before viral entry into cells, (v) antibody production and/or (vi) targeting and protecting beneficial cells.
  • lymphocytes include T-cells, B cells, natural killer (NK) cells, monocytes/macrophages and hematopoietic stem cells.
  • lymphocyte-directing agents achieve selective direction to particular lymphocyte populations through receptor-mediated endocytosis.
  • TCR T-cell receptor
  • the actual T-cell receptor is composed of two separate peptide chains, which are produced from the independent T-cell receptor alpha and beta (TCR ⁇ and TCR ⁇ ) genes and are called ⁇ - and ⁇ -TCR chains.
  • Lymphocyte directing agents disclosed herein can bind ⁇ - and/or ⁇ -TCR chains to achieve selective delivery of a polynucleotide to these T cells.
  • ⁇ T-cells represent a small subset of T-cells that possess a distinct T-cell receptor (TCR) on their surface.
  • TCR T-cell receptor
  • the TCR is made up of one ⁇ -chain and one ⁇ -chain. This group of T-cells is much less common (2% of total T-cells) than the ⁇ -cells. Nonetheless, lymphocyte-directing agents disclosed herein can bind ⁇ - and/or ⁇ TCR chains to achieve selective delivery of a polynucleotide to these T cells.
  • CD3 is expressed on all mature T cells. Accordingly, lymphocyte-directing agents disclosed herein can bind CD3 to achieve selective delivery of a polynucleotide to all mature T-cells. Activated T-cells express 4-1BB (CD137). Accordingly, lymphocyte-directing agents disclosed herein can bind 4-1 BB to achieve selective delivery of a polynucleotide to activated T-cells. CD5 and transferrin receptor are also expressed on T-cells and can be used to achieve selective delivery of a polynucleotide to T-cells.
  • T-cells can further be classified into helper cells (CD4+ T-cells) and cytotoxic T-cells (CTLs, CD8+ T-cells), which comprise cytolytic T-cells.
  • T helper cells assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and activation of cytotoxic T-cells and macrophages, among other functions. These cells are also known as CD4+ T-cells because they express the CD4 protein on their surface.
  • Helper T-cells become activated when they are presented with peptide antigens by MHC class II molecules that are expressed on the surface of antigen presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response. Lymphocyte-directing agents disclosed herein can bind CD4 to achieve selective delivery of a polynucleotide to T helper cells.
  • Cytotoxic T-cells destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T-cells because they express the CD8 glycoprotein at their surface. These cells recognize their targets by binding to antigen associated with MHC class I, which is present on the surface of nearly every cell of the body. Lymphocyte-directing agents disclosed herein can bind CD8 to achieve selective delivery of a polynucleotide to CTL.
  • Central memory T-cells refers to an antigen experienced CTL that expresses CD62L or CCR7 and CD45RO on the surface thereof, and does not express or has decreased expression of CD45RA as compared to naive cells.
  • central memory cells are positive for expression of CD62L, CCR7, CD25, CD127, CD45RO, and CD95, and have decreased expression of CD45RA as compared to naive cells.
  • Lymphocyte-directing agents disclosed herein can bind CD62L, CCR7, CD25, CD127, CD45RO and/or CD95 to achieve selective delivery of a polynucleotide to T CM .
  • “Effector memory” T-cell refers to an antigen experienced T-cell that does not express or has decreased expression of CD62L on the surface thereof as compared to central memory cells, and does not express or has decreased expression of CD45RA as compared to a naive cell.
  • effector memory cells are negative for expression of CD62L and CCR7, compared to naive cells or central memory cells, and have variable expression of CD28 and CD45RA.
  • Effector T-cells are positive for granzyme B and perforin as compared to memory or naive T-cells.
  • Lymphocyte-directing agents disclosed herein can bind granzyme B and/or perform to achieve selective delivery of a polynucleotide to T EM .
  • T REG Regulatory T cells
  • T REG Regulatory T cells
  • T REG express CD25, CTLA-4, GITR, GARP and LAP.
  • Lymphocyte-directing agents disclosed herein can bind CD25, CTLA-4, GITR, GARP and/or LAP to achieve selective delivery of a polynucleotide to na ⁇ ve T REG .
  • naive T-cells refers to a non-antigen experienced T cell that expresses CD62L and CD45RA, and does not express CD45RO as compared to central or effector memory cells.
  • naive CD8+ T lymphocytes are characterized by the expression of phenotypic markers of na ⁇ ve T-cells including CD62L, CCR7, CD28, CD127, and CD45RA. Lymphocyte-directing agents disclosed herein can bind CD62L, CCR7, CD28, CD127 and/or CD45RA to achieve selective delivery of a polynucleotide to na ⁇ ve T-cells.
  • Natural killer cells also known as NK cells, K cells, and killer cells
  • NK cells are activated in response to interferons or macrophage-derived cytokines. They serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection.
  • NK cells express CD8, CD16 and CD56 but do not express CD3.
  • Lymphocyte-directing agents disclosed herein can bind CD8, CD16 and/or CD56 to achieve selective delivery of a polynucleotide to NK cells.
  • Macrophages (and their precursors, monocytes) reside in every tissue of the body (in certain instances as microglia, Kupffer cells and osteoclasts) where they engulf apoptotic cells, pathogens and other non-self components. Because monocytes/macrophages engulf non-self components, a particular macrophage- or monocyte-directing agent is not required on the nanocarriers described herein for selective uptake by these cells.
  • lymphocyte-directing agents disclosed herein can bind CD11b, F4/80; CD68; CD11c; IL-4R ⁇ ; and/or CD163 to achieve selective delivery of a polynucleotide to monocytes/macrophages.
  • B cells can be distinguished from other lymphocytes by the presence of the B cell receptor (BCR).
  • BCR B cell receptor
  • the principal function of B cells is to make antibodies.
  • B cells express CD5, CD19, CD20, CD21, CD22, CD35, CD40, CD52, and CD80.
  • Lymphocyte-directing agents disclosed herein can bind CD5, CD19, CD20, CD21, CD22, CD35, CD40, CD52, and/or CD80 to achieve selective delivery of a polynucleotide to B-cells.
  • Lymphocyte function-associated antigen 1 (LFA-1) is expressed by all T-cells, B-cells and monocytes/macrophages. Accordingly, lymphocyte-directing agents disclosed herein can bind LFA-1to achieve selective delivery of a polynucleotide to T-cells, B-cells and monocytes/macrophages.
  • Hematopoietic stem cells can also be targeted for selective delivery of nanocarriers disclosed herein.
  • Hematopoietic stem cells express CD34, CD133, Sca-1 and CD117.
  • Lymphocyte-directing agents disclosed herein can bind CD34, CD133, Sca-1 and/or CD117 to achieve selective delivery of a polynucleotide to hematopoietic stem cells.
  • “Selective delivery” means that polynucleotides are delivered and expressed by one or more selected lymphocyte populations. In particular embodiments, selective delivery is exclusive to a selected lymphocyte population. In further embodiments, at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% of administered polynucleotides are delivered and/or expressed by a selected lymphocyte population. In further embodiments, selective delivery ensures that non-lymphocyte cells do not express delivered polynucleotides. For example, when the targeting agent is a T-cell receptor (TCR) gene, selectivity is ensured because only T cells have the zeta chains required for TCR expression.
  • TCR T-cell receptor
  • Selective delivery can also be based on lack of polynucleotide uptake into unselected cells or based on the presence of a specific promoter within the polynucleotide sequence when the polynucleotide includes plasmid DNA.
  • plasmid DNA can include a T-cell-specific CD3-delta promoter.
  • Additional promoters that can achieve selective delivery include: the murine stem cell virus promoter or the distal Ick promoter for T cells or hematopoietic stem cells; the CD45 promoter, WASP promoter or IFN-beta promoter for hematopoietic stem cells; the B29 promoter for B cells; or the CD14 promoter or the CD11b promoter for monocytes/macrophages.
  • lymphocyte-directing agents can include binding domains for motifs found on lymphocyte cells. Lymphocyte-directing agents can also include any selective binding mechanism allowing selective uptake into lymphocytes.
  • lymphocyte-directing agents include binding domains for T-cell receptor motifs; T-cell ⁇ chains; T-cell ⁇ chains; T-cell ⁇ chains; T-cell ⁇ chains; CCR7; CD3; CD4; CD5; CD7; CD8; CD11b; CD11c; CD16; CD19; CD20; CD21; CD22; CD25; CD28; CD34; CD35; CD40; CD45RA; CD45RO; CD52; CD56; CD62L; CD68;CD80; CD95; CD117; CD127; CD133; CD137 (4-1BB); CD163; F4/80; IL-4R ⁇ ; Sca-1; CTLA-4; GITR; GARP; LAP; granzyme B; LFA-1; transferrin receptor; and combinations thereof.
  • binding domains include cell marker ligands, receptor ligands, antibodies, peptides, peptide aptamers, nucleic acids, nucleic acid aptamers, spiegelmers or combinations thereof.
  • binding domains include any substance that binds to another substance to form a complex capable of mediating endocytosis.
  • Antibodies are one example of binding domains and include whole antibodies or binding fragments of an antibody, e.g., Fv, Fab, Fab′, F(ab′) 2 , Fc, and single chain Fv fragments (scFvs) or any biologically effective fragments of an immunoglobulin that bind specifically to a motif expressed by a lymphocyte.
  • Antibodies or antigen binding fragments include all or a portion of polyclonal antibodies, monoclonal antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, bispecific antibodies, mini bodies, and linear antibodies.
  • Antibodies from human origin or humanized antibodies have lowered or no immunogenicity in humans and have a lower number of non-immunogenic epitopes compared to non-human antibodies.
  • Antibodies and their fragments will generally be selected to have a reduced level or no antigenicity in human subjects.
  • Antibodies that specifically bind a motif expressed by a lymphocyte can be prepared using methods of obtaining monoclonal antibodies, methods of phage display, methods to generate human or humanized antibodies, or methods using a transgenic animal or plant engineered to produce antibodies as is known to those of ordinary skill in the art (see, for example, U.S. Pat. Nos. 6,291,161 and 6,291,158).
  • Phage display libraries of partially or fully synthetic antibodies are available and can be screened for an antibody or fragment thereof that can bind to a lymphocyte motif. For example, binding domains may be identified by screening a Fab phage library for Fab fragments that specifically bind to a target of interest (see Hoet et al., Nat. Biotechnol. 23:344, 2005).
  • Phage display libraries of human antibodies are also available. Additionally, traditional strategies for hybridoma development using a target of interest as an immunogen in convenient systems (e.g., mice, HuMAb mouse®, TC mouseTM, KM-mouse®, llamas, chicken, rats, hamsters, rabbits, etc.) can be used to develop binding domains. In particular embodiments, antibodies specifically bind to motifs expressed by a selected lymphocyte and do not cross react with nonspecific components or unrelated targets. Once identified, the amino acid sequence or polynucleotide sequence coding for the antibody can be isolated and/or determined.
  • binding domains of lymphocyte-directing agents include T-cell receptor motif antibodies; T-cell ⁇ chain antibodies; T-cell ⁇ chain antibodies; T-cell ⁇ chain antibodies; T-cell ⁇ chain antibodies; CCR7 antibodies; CD3 antibodies; CD4 antibodies; CD5 antibodies; CD7 antibodies; CD8 antibodies; CD11b antibodies; CD11c antibodies; CD16 antibodies; CD19 antibodies; CD20 antibodies; CD21 antibodies; CD22 antibodies; CD25 antibodies; CD28 antibodies; CD34 antibodies; CD35 antibodies; CD40 antibodies; CD45RA antibodies; CD45R0 antibodies; CD52 antibodies; CD56 antibodies; CD62L antibodies; CD68 antibodies; CD80 antibodies; CD95 antibodies; CD117 antibodies; CD127 antibodies; CD133 antibodies; CD137 (4-1BB) antibodies; CD163 antibodies; F4/80 antibodies; IL-4R ⁇ antibodies; Sca-1 antibodies; CTLA-4 antibodies; GITR antibodies GARP antibodies; LAP antibodies; granzyme B antibodies; LFA-1 antibodies; or transferrin receptor antibodies.
  • binding domains also can consist of scFv fragments of the foregoing antibodies.
  • the lymphocyte-directing agent binding domain includes the scFv fragment (SEQ ID NO. 1) of the PSMA-specific chimeric antigen receptor (CAR), P28z.
  • Peptide aptamers include a peptide loop (which is specific for a target protein) attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the peptide aptamer to levels comparable to an antibody.
  • the variable loop length is typically 8 to 20 amino acids (e.g., 8 to 12 amino acids), and the scaffold may be any protein which is stable, soluble, small, and non-toxic (e.g., thioredoxin-A, stefin A triple mutant, green fluorescent protein, eglin C, and cellular transcription factor Spl).
  • Peptide aptamer selection can be made using different systems, such as the yeast two-hybrid system (e.g., Gal4 yeast-two-hybrid system) or the LexA interaction trap system.
  • Nucleic acid aptamers are single-stranded nucleic acid (DNA or RNA) ligands that function by folding into a specific globular structure that dictates binding to target proteins or other molecules with high affinity and specificity, as described by Osborne et al., Curr. Opin. Chem. Biol. 1:5-9, 1997; and Cerchia et al., FEBS Letters 528:12-16, 2002.
  • aptamers are small ( ⁇ 15 KD; or between 15-80 nucleotides or between 20-50 nucleotides).
  • Aptamers are generally isolated from libraries consisting of 10 14 -10 15 random oligonucleotide sequences by a procedure termed SELEX (systematic evolution of ligands by exponential enrichment; see, for example, Tuerk et al., Science, 249:505-510, 1990; Green et al., Methods Enzymology. 75-86, 1991; and Gold et al., Annu. Rev. Biochem., 64: 763-797, 1995). Further methods of generating aptamers are described in, for example, U.S. Pat. Nos.
  • lymphocytes Other agents that can facilitate internalization by and/or transfection of lymphocytes, such as poly(ethyleneimine)/DNA (PEI/DNA) complexes can also be used.
  • PEI/DNA poly(ethyleneimine)/DNA
  • polynucleotide includes a nucleic acid molecule that contains a nucleic acid sequence such that upon introduction into a targeted lymphocyte, the nucleic acid molecule can cause transcription and resulting translation of targeting agents encoded by the nucleic acid sequence of the nucleic acid molecule.
  • the targeting agent is an unwanted cell targeting agent.
  • the targeting agent is a wanted cell targeting agent.
  • the term “gene” refers to a nucleic acid sequence that encodes a targeting agent. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein such alterations do not affect the function of the encoded targeting agent.
  • the term “gene” may include not only coding sequences but also regulatory regions such as promoters, enhancers, and termination regions. The term further can include all introns and other DNA sequences spliced from the mRNA transcript, along with variants resulting from alternative splice sites.
  • Nucleic acid sequences encoding the targeting agent can be DNA or RNA that directs the expression of the targeting agent.
  • nucleic acid sequences may be a DNA strand sequence that is transcribed into RNA or an RNA sequence that is translated into protein.
  • the nucleic acid sequences include both the full-length nucleic acid sequences as well as non-full-length sequences derived from the full-length protein.
  • the sequences can also include degenerate codons of the native sequence or sequences that may be introduced to provide codon preference in a specific lymphocyte.
  • Gene sequences to encode targeting agents disclosed herein are available in publicly available databases and publications, incorporated by reference herein.
  • the term “encoding” refers to a property of sequences of nucleotides in a polynucleotide, such as a plasmid, a gene, cDNA, mRNA, to serve as templates for synthesis of targeting agents.
  • a polynucleotide can, e.g., encode a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system.
  • polynucleotides having a sequence encoding a targeting agent include all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
  • the polynucleotides that encode proteins and RNA can also include introns.
  • the polynucleotide includes a plasmid, a cDNA, or an mRNA that can include, e.g., a sequence (e.g., a gene) for expressing a targeting agent.
  • Suitable plasmids include standard plasmid vectors and minicircle plasmids that can be used to transfer a gene to a lymphocyte.
  • the polynucleotides e.g., minicircle plasmids
  • the polynucleotides can include promoters, such as general promoters, tissue-specific promoters, cell-specific promoters, and/or promoters specific for the nucleus or cytoplasm. Promoters and plasmids (e.g., minicircle plasmids) are generally well known in the art and can be prepared using conventional techniques.
  • the polynucleotides can be used to transfect lymphocytes. Unless otherwise specified, the terms transfect, transfected, or transfecting can be used to indicate the presence of exogenous polynucleotides or the expressed polypeptide therefrom in a lymphocyte.
  • a number of vectors are known to be capable of mediating transfer of genes to lymphocytes, as is known in the art.
  • the transfected polynucleotides can edit the antigen-specificity of lymphocytes without affecting off-target bystander cells (i.e., provide for selective delivery as defined herein).
  • delivered genes can be expressed under the control of a lymphocyte-specific promoter.
  • the promoters can be included in minicircle plasmids that are a form of supercoiled DNA molecule for nonviral gene transfer, which have neither bacterial origin of replication nor antibiotic resistance marker. They are thus smaller and potentially safer than the standard plasmids currently used in gene therapy.
  • a scaffold/matrix attachment region can also be inserted into the polynucleotides.
  • Polynucleotides containing an expression cassette linked to a S/MAR element can autonomously replicate extra-chromosomally in dividing cells.
  • PiggyBac or Sleeping Beauty transposase-containing plasmids can also be used to stably integrate nanocarrier-delivered targeting agent genes into the genome of transfected lymphocytes.
  • Other options to sustain expression include homo sapiens transposon-derived Buster1 transposase-like protein gene; human endogenous retrovirus H protease/integrase-derived ORF1; homo sapiens Cas-Br-M (murine) ecotropic retroviral transforming sequence; homo sapiens endogenous retroviral sequence K; homo sapiens endogenous retroviral family W; homo sapiens LINE-1 type transposase domain; or homo sapiens pogo transposable element.
  • a delivered polynucleotide is mRNA
  • backbone modifications can increase the mRNA's stability making resistant to premature cleavage.
  • Targeted Cells & Associated Markers can be unwanted cells or wanted cells.
  • Unwanted cells include any cell type that is (i) capable of recognition and destruction by the immune system; and (ii) deemed undesirable by a subject, physician, veterinarian or researcher.
  • Unwanted cells include (i) eukaryotic cells that are either cancerous or infected with a pathogen such as a virus and (ii) prokaryotic cells, such as certain bacteria, fungi or yeast.
  • Wanted cells include any cell type that is (i) capable of recognition and protection by the immune system; and (ii) deemed desirable by a subject, physician, veterinarian or researcher.
  • Wanted cells can include cells undergoing auto-immune attack or bacteria that are beneficial to the health of a microbiome.
  • the markers are antigens.
  • Antigens refer to substances capable of either binding to an antigen binding region of an immunoglobulin molecule or of eliciting an immune response, e.g., a T cell-mediated immune response by the presentation of the antigen on Major Histocompatibility Antigen (MHC) cellular proteins.
  • MHC Major Histocompatibility Antigen
  • Antigens include antigenic determinants, haptens, and immunogens, which may be peptides, small molecules, carbohydrates, lipids, nucleic acids or combinations thereof.
  • the term “antigen” refers to those portions of the antigen (e.g., a peptide fragment) that is a T cell epitope presented by MHC to the T cell receptor.
  • the portion of the antigen that binds to the complementarity determining regions of the variable domains of the antibody (light and heavy) is referenced.
  • the bound portion may be a linear or three-dimensional epitope.
  • markers are expressed by unwanted cells from cancers.
  • Exemplary cancers include adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, non-Hodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas
  • Particular antigen markers associated with cancers cells include A33; BAGE; Bcl-2; ⁇ -catenin; CAl25; CA19-9; CD5; CD19; CD20; CD21; CD22; CD33; CD37; CD45; CD123; CEA; c-Met; CS-1; cyclin B1; DAGE; EBNA; EGFR; ephrinB2; estrogen receptor; FAP; ferritin; folate-binding protein; GAGE; G250; GD-2; GM2; gp75, gp100 (Pmel 17); HER-2/neu; HPV E6; HPV E7; Ki-67; LRP; mesothelin, p53, PRAME; progesterone receptor; PSA; PSMA; MAGE; MART; mesothelin; MUC; MUM-1-B; myc; NYESO-1; ras; RORI; survivin; tenascin; TSTA tyrosinas
  • the particular following cancers can be treated by targeting the associated provided antigens: leukemia/lymphoma (CD19, CD20, CD22, ROR1, CD33); multiple myeloma (B-cell maturation antigen (BCMA)); prostate cancer (PSMA, WT1, Prostate Stem Cell antigen (PSCA), SV40 T); breast cancer (HER2, ERBB2); stem cell cancer (CD133); ovarian cancer (L1-CAM, extracellular domain of MUC16 (MUC-CD), folate binding protein (folate receptor), Lewis Y); renal cell carcinoma (carboxy-anhydrase-IX (CAIX); melanoma (GD2); and pancreatic cancer (mesothelin, CEA, CD24).
  • B-cell maturation antigen BCMA
  • PSMA WT1, Prostate Stem Cell antigen
  • SV40 T breast cancer
  • HER2, ERBB2 stem cell cancer
  • CD133 ovarian cancer
  • L1-CAM extracellular domain of MUC16
  • cancer cell antigens include:
  • modified T cells, NK cells and/or monocytes/macrophages target and destroy cancer cells.
  • B cells can also be modified to secrete tumor-specific antibodies.
  • markers are expressed by unwanted virally-infected cells.
  • exemplary viruses include adenoviruses, arenaviruses, bunyaviruses, coronavirusess, flavirviruses, hantaviruses, hepadnaviruses, herpesviruses, papilomaviruses, paramyxoviruses, parvoviruses, picornaviruses, poxviruses, orthomyxoviruses, retroviruses, reoviruses, rhabdoviruses, rotaviruses, spongiform viruses or togaviruses.
  • viral antigen markers include peptides expressed by CMV, cold viruses, Epstein-Barr, flu viruses, hepatitis A, B, and C viruses, herpes simplex, HIV, influenza, Japanese encephalitis, measles, polio, rabies, respiratory syncytial, rubella, smallpox, varicella zoster or West Nile virus.
  • cytomegaloviral antigens include envelope glycoprotein B and CMV pp65; Epstein-Barr antigens include EBV EBNAI, EBV P18, and EBV P23; hepatitis antigens include the S, M, and L proteins of hepatitis B virus, the pre-S antigen of hepatitis B virus, HBCAG DELTA, HBV HBE, hepatitis C viral RNA, HCV NS3 and HCV NS4; herpes simplex viral antigens include immediate early proteins and glycoprotein D; HIV antigens include gene products of the gag, pol, and env genes such as HIV gp32, HIV gp41, HIV gp120, HIV gp160, HIV P17/24, HIV P24, HIV P55 GAG, HIV P66 POL, HIV TAT, HIV GP36, the Nef protein and reverse transcriptase; influenza antigens include hemagglutinin and neuraminidase; Japanese
  • viral antigen sequences include:
  • Nef (66-97): VGFPVTPQVPLRPMTYKAAVDLSH 9 FLKEKGGL Nef (116-145) HTQGYFPDWQNYTPGPGVRYPLTF 10 GWLYKL Gag p17 (17-35) EKIRLRPGGKKKYKLKHIV 11 Gag p17-p24 NPPIPVGEIYKRWIILGLNKIVRM 12 (253-284) YSPTSILD Pol 325-355 AIFQSSMTKILEPFRKQNPDIVI 13 (RT 158-188) YQYMDDLY See Fundamental Virology, Second Edition, eds. Fields, B. N. and Knipe, D. M. (Raven Press, New York, 1991) for additional examples of viral antigens.
  • modified T cells recognize and destroy virally-infected cells.
  • modified monocytes/macrophages can remove viruses from peripheral tissue or the blood stream (extracellular) before cellular infection by a viral particle.
  • B cells can also be modified to express broadly neutralizing antibodies.
  • B cells can be modified to express broadly neutralizing anti-HIV antibodies.
  • the targeting agent targets HIV gag protein, gp120 or the Hepatitis B envelope protein (S domain).
  • markers are expressed by cells associated with unwanted bacterial infections.
  • Exemplary bacteria include anthrax; gram-negative bacilli, chlamydia, diptheria, haemophilus influenza, Helicobacter pylori, malaria, Mycobacterium tuberculosis , pertussis toxin, pneumococcus, rickettsiae, staphylococcus, streptococcus and tetanus.
  • anthrax antigens include anthrax protective antigen; gram-negative bacilli antigens include lipopolysaccharides; haemophilus influenza antigens include capsular polysaccharides; diptheria antigens include diptheria toxin; Mycobacterium tuberculosis antigens include mycolic acid, heat shock protein 65 (HSP65), the 30 kDa major secreted protein and antigen 85A; pertussis toxin antigens include hemagglutinin, pertactin, FIM2, FIM3 and adenylate cyclase; pneumococcal antigens include pneumolysin and pneumococcal capsular polysaccharides; rickettsiae antigens include rompA; streptococcal antigens include M proteins; and tetanus antigens include tetanus toxin.
  • HSP65 heat shock protein 65
  • bacteria cells can also be wanted cell types.
  • Monocytes/macrophages are particularly useful to modify when the therapeutic objective is treatment of a bacterial infection.
  • monocytes/macrophages can be modified with a ligand recognizing the surface component lipoteichoic acid of Staphyloccus aureus or the Staphylococcus aureus clumping factor A (CIfA).
  • Immunosuppressive T REG can be useful to modify when a bacteria is a wanted cell type.
  • lymphocytes are modified to target multi-drug resistant “superbugs”.
  • superbugs include Enterococcus faecium, Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacteriaceae (including Escherichia coli, Klebsiella pneumoniae, Enterobacter spp.).
  • markers are expressed by cells associated with unwanted fungal infections.
  • fungi include candida, coccidiodes, cryptococcus, histoplasma, leishmania, plasmodium, protozoa, parasites, schistosomae, tinea, toxoplasma, and trypanosoma cruzi.
  • coccidiodes antigens include spherule antigens; cryptococcal antigens include capsular polysaccharides; histoplasma antigens include heat shock protein 60 (HSP60); leishmania antigens include gp63 and lipophosphoglycan; plasmodium falciparum antigens include merozoite surface antigens, sporozoite surface antigens, circumsporozoite antigens, gametocyte/gamete surface antigens, protozoal and other parasitic antigens including the blood-stage antigen pf 155/RESA; schistosomae antigens include glutathione-S-transferase and paramyosin; tinea fungal antigens include trichophytin; toxoplasma antigens include SAG-1 and p30; and trypanosoma cruzi antigens include the 75-77 kDa antigen and the 56 kDa antigen.
  • HSP60 heat shock protein 60
  • Monocytes/macrophages are particularly useful to modify when the therapeutic objective is treatment of a fungal infection.
  • markers are expressed by cells associated with unwanted autoimmune or allergic conditions.
  • autoimmune conditions include acute necrotizing hemorrhagic encephalopathy, allergic asthma, alopecia areata, anemia, aphthous ulcer, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), asthma, autoimmune thyroiditis, conjunctivitis, Crohn's disease, cutaneous lupus erythematosus, dermatitis (including atopic dermatitis and eczematous dermatitis), diabetes, diabetes mellitus, erythema nodosum leprosum, keratoconjunctivitis, multiple sclerosis, myasthenia gravis, psoriasis, scleroderma, Sjogren's syndrome, including keratoconjunctivitis sicca secondary to Sjogren
  • autoimmune antigens examples include glutamic acid decarboxylase 65 (GAD 65), native DNA, myelin basic protein, myelin proteolipid protein, acetylcholine receptor components, thyroglobulin, and the thyroid stimulating hormone (TSH) receptor.
  • GID 65 glutamic acid decarboxylase 65
  • native DNA myelin basic protein
  • myelin proteolipid protein acetylcholine receptor components
  • thyroglobulin thyroglobulin
  • TSH thyroid stimulating hormone
  • allergic antigens include pollen antigens such as Japanese cedar pollen antigens, ragweed pollen antigens, rye grass pollen antigens, animal derived antigens (such as dust mite antigens and feline antigens), histocompatibility antigens, and penicillin and other therapeutic drugs.
  • Immunosuppressive T REG can be useful to modify to protect wanted cells from autoimmune attack or to reduce immune system activity in an area.
  • exemplary wanted cells to protect from autoimmune attack include neurons in multiple sclerosis or amylotrophic lateral sclerosis; connective tissue in rheumatoid arthritis; colon epithelium in Chrohn's disease; and the pancreas in Diabetes mellitus type 1.
  • T REG are modified to express a chimeric antigen receptor (CAR) against KIR4.1 (a potassium channel) that has been identified as an immune target in multiple sclerosis.
  • CAR chimeric antigen receptor
  • markers can also include B-cell targets, TNF receptor superfamily members, Hedgehog family members, receptor tyrosine kinases, proteoglycan-related molecules, TGF- ⁇ superfamily members, Wnt-related molecules, T-cell targets, dendritic cell targets, NK cell targets, a monocyte/macrophage cell targets, and angiogenesis targets.
  • markers can also include CEACAM6, c-Met, EGFR, ErbB2, ErbB3, ErbB4, EphA2, IGF1R, GHRHR, GHR, FLT1, KDR, FLT4, CD44v6, CAl25, CEA, BTLA, TGFBR2, TGFBR1, IL6R, gp130, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, mesothelin, PSMA, RANK, ROR1, TNFRSF4, TWEAK-R, HLA, tumor or pathogen derived peptides bound to HLA (such as from hTERT, tyrosinase, or WT-1), LT ⁇ R, LIFR ⁇ , LRP5, MUC1, OSMR ⁇ , TCR ⁇ , TCR ⁇ , B7H4, TLR7, TLR9, PTCH1, PTCH1, Robo1, ⁇ -fetoprotein (AFP) or Frizzled
  • Targeting agents include any binding domain capable of (i) expression by a lymphocyte; and (ii) binding to a marker associated with a target. Binding of the targeting agent to the marker then mediates destruction or protection of the target.
  • Binding domains include any substance that binds to another substance to form a complex.
  • binding domains include cell marker ligands, receptor ligands, antibodies, peptides, peptide aptamers, receptors and chimeric antigen receptors (CAR) or combinations thereof.
  • targeting agent binding domains can include the same components, options and identification methods as described above in relation to lymphocyte-directing agent binding domains with altered specificity, as appropriate.
  • Targeting agent binding domains can particularly include any peptide that specifically binds a marker on a targeted cell.
  • Sources of targeting agent binding domains include antibody variable regions from various species (which can be in the form of antibodies, sFvs, scFvs, Fabs, scFv-based grababody, or soluble VH domain or domain antibodies). These antibodies can form antigen-binding regions using only a heavy chain variable region, i.e., these functional antibodies are homodimers of heavy chains only (referred to as “heavy chain antibodies”) (Jespers et al., Nat. Biotechnol. 22:1161, 2004; Cortez-Retamozo et al., Cancer Res. 64:2853, 2004; Baral et al., Nature Med. 12:580, 2006; and Barthelemy et al., J. Biol. Chem. 283:3639, 2008).
  • An alternative source of targeting agent binding domains includes sequences that encode random peptide libraries or sequences that encode an engineered diversity of amino acids in loop regions of alternative non-antibody scaffolds, such as scTCR (see, e.g., Lake et al., Int. Immunol. 11:745, 1999; Maynard et al., J. Immunol. Methods 306:51, 2005; U.S. Pat. No. 8,361,794), fibrinogen domains (see, e.g., Shoesl et al., Science 230:1388, 1985), Kunitz domains (see, e.g., U.S. Pat. No.
  • scTCR see, e.g., Lake et al., Int. Immunol. 11:745, 1999; Maynard et al., J. Immunol. Methods 306:51, 2005; U.S. Pat. No. 8,361,794
  • fibrinogen domains see, e.g.
  • mAb 2 or FcabTM see, e.g., PCT Patent Application Publication Nos. WO 2007/098934; WO 2006/072620
  • armadillo repeat proteins see, e.g., Madhurantakam et al., Protein Sci. 21: 1015, 2012; PCT Patent Application Publication No. WO 2009/040338
  • affilin Edbersbach et al., J. Mol. Biol. 372: 172, 2007
  • affibody avimers, knottins, fynomers, atrimers, cytotoxic T-lymphocyte associated protein-4 (Weidle et al., Cancer Gen. Proteo.
  • a binding domain is a single chain T cell receptor (scTCR) comprising V ⁇ / ⁇ and C ⁇ / ⁇ chains (e.g., V ⁇ -C ⁇ , V ⁇ -C ⁇ , V ⁇ -V ⁇ ) or comprising V ⁇ -C ⁇ , V ⁇ -C ⁇ , V ⁇ -V ⁇ pair specific for a target of interest (e.g., peptide-MHC complex).
  • scTCR single chain T cell receptor
  • the targeting agent is an unwanted cell targeting agent and the binding domain can be an antibody targeting PSMA.
  • a number of antibodies specific for PSMA are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity.
  • Unwanted cell targeting agent binding domains can also include anti-Mesothelin ligands (associated with treating ovarian cancer, pancreatic cancer, and mesothelioma); anti-WT-1 (associated with treating leukemia and ovarian cancer); anti-HIV-gag (associated with treating HIV infections); or anti-cytomegalovirus (associated with treating CMV diseases such as herpes virus).
  • the unwanted cell targeting agent binding domain can be any ligand that binds to any marker associated with an unwanted cell type as described herein.
  • the targeting agent is an unwanted cell targeting agent and the binding domain can be an antibody targeting CD19.
  • a binding domain is a single chain Fv fragment (scFv) that comprises VH and VL regions specific for CD19.
  • the V H and V L regions are human.
  • Exemplary V H and V L regions include the segments of anti-CD19 specific monoclonal antibody FMC63.
  • the scFV is a human or humanized ss comprising a variable light chain comprising a CDRL1 sequence of RASQDISKYLN (SEQ ID NO. 14), CDRL2 sequence of SRLHSGV (SEQ ID NO. 15), and a CDRL3 sequence of GNTLPYTFG (SEQ ID NO.
  • the scFV is a human or humanized ScFv comprising a variable heavy chain comprising CDRHI sequence of DYGVS (SEQ ID NO. 17), CDRH2 sequence of VTWGSETTYYNSALKS (SEQ ID NO. 18), and a CDRH3 sequence of YAMDYWG (SEQ ID NO. 19).
  • CD19-targeting antibodies such as SJ25C1 and HD37 are known. (SJ25C1: Bejcek et al. Cancer Res 2005, PMID 7538901; HD37: Pezutto et al. JI 1987, PMID 2437199).
  • SEQ ID NO. 20 provides the anti-CD19 scFv (VH-VL) FMC63 DNA sequence
  • SEQ ID NO. 21 provides the anti-CD19 scFv (VH-VL) FMC63 amino acid sequence.
  • the targeting agent is an unwanted cell targeting agent and the binding domain can be an antibody targeting RORI.
  • the scFV is a human or humanized scFv comprising a variable light chain comprising a CDRL1 sequence of ASGFDFSAYYM (SEQ ID NO. 22), CDRL2 sequence of TIYPSSG (SEQ ID NO. 23), and a CDRL3 sequence of ADRATYFCA (SEQ ID NO. 24).
  • the scFV is a human or humanized scFv comprising a variable heavy chain comprising CDRH1 sequence of DTIDWY (SEQ ID NO. 25), CDRH2 sequence of VQSDGSYTKRPGVPDR (SEQ ID NO. 26), and a CDRH3 sequence of YIGGYVFG (SEQ ID NO. 27).
  • a number of antibodies specific for RORI are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity.
  • targeting agent binding domains comprise a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identical to an amino acid sequence of a TCR V ⁇ , V ⁇ , C ⁇ , or C ⁇ , wherein each CDR comprises zero changes or at most one, two, or three changes, from a TCR or fragment or derivative thereof that specifically binds to target of interest.
  • targeting agent binding domain V ⁇ , V ⁇ , C ⁇ , or C ⁇ region of the present disclosure can be derived from or based on a V ⁇ , V ⁇ , C ⁇ , or C ⁇ of a known TCR (e.g., a high-affinity TCR) and contains one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V ⁇ , V ⁇ , C ⁇ , or C ⁇ of a known TCR.
  • a known TCR e.g., a high-affinity TCR
  • amino acid substitutions e.g., conservative amino acid substitutions or non
  • An insertion, deletion or substitution may be anywhere in a V ⁇ , V ⁇ , C ⁇ , or C ⁇ region, including at the amino- or carboxy-terminus or both ends of these regions, provided that each CDR comprises zero changes or at most one, two, or three changes and provided a binding domain containing a modified V ⁇ , V ⁇ , C ⁇ , or C ⁇ region can still specifically bind its target with an affinity similar to wild type.
  • a binding domain V H region of the present disclosure can be derived from or based on a V H of a known monoclonal antibody and can contain one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V H of a known monoclonal antibody.
  • one or more e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above
  • An insertion, deletion or substitution may be anywhere in the V H region, including at the amino- or carboxy-terminus or both ends of this region, provided that each CDR comprises zero changes or at most one, two, or three changes and provided a binding domain containing the modified V H region can still specifically bind its target with an affinity similar to the wild type binding domain.
  • a V L region in a binding domain of the present disclosure is derived from or based on a V L of a known monoclonal antibody and contains one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V L of the known monoclonal antibody.
  • An insertion, deletion or substitution may be anywhere in the V L region, including at the amino- or carboxy-terminus or both ends of this region, provided that each CDR comprises zero changes or at most one, two, or three changes and provided a binding domain containing the modified V L region can still specifically bind its target with an affinity similar to the wild type binding domain.
  • a binding domain comprises or is a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identical to an amino acid sequence of a light chain variable region (V L ) or to a heavy chain variable region (V H ), or both, wherein each CDR comprises zero changes or at most one, two, or three changes, from a monoclonal antibody or fragment or derivative thereof that specifically binds to target of interest.
  • V L light chain variable region
  • V H heavy chain variable region
  • cell-targeting agents disclosed herein include chimeric antigen receptors.
  • Chimeric antigen receptors or “CARs” refer to synthetically designed receptors comprising at least a binding domain and an effector domain and optionally a spacer domain and/or a transmembrane domain. Binding domains are described elsewhere herein.
  • Effector domains are capable of transmitting functional signals to a cell.
  • an effector domain will directly or indirectly promote a cellular response by associating with one or more other proteins that directly promote a cellular response.
  • Effector domains can provide for activation of at least one function of a transduced lymphocyte expressing the CAR upon binding to the marker expressed on a targeted cell.
  • Activation of the lymphocyte can include one or more of proliferation, differentiation, activation or other effector functions.
  • the delivered polynucleotide encodes for the effector domain.
  • An effector domain may include one, two, three or more receptor signaling domains, intracellular signaling domains, costimulatory domains, or combinations thereof. Any intracellular effector domain, costimulatory domain or both from any of a variety of signaling molecules (e.g., signal transduction receptors) may be used in the CARs of this disclosure.
  • signaling molecules e.g., signal transduction receptors
  • Exemplary effector domains include those from 4-1BB, CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD27, CD28 (e.g., SEQ ID NO.:28), CD79A, CD79B, CARD11, DAP10, FcR ⁇ , FcR ⁇ , FcR ⁇ , Fyn, HVEM, ICOS, Lck, LAG3, LAT, LRP, NOTCH1, Wnt, NKG2D, OX40, ROR2, Ryk, SLAMF1, Slp76, pTa, TCR ⁇ , TCR ⁇ , TRIM, Zap70, PTCH2, or any combination thereof.
  • T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequence: those that initiate antigen-dependent primary activation and provide a T cell receptor like signal (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic signaling sequences).
  • Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs which are known as receptor tyrosine-based activation motifs or iTAMs.
  • iTAM containing primary cytoplasmic signaling sequences include those derived from CD3 zeta, FeR gamma, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d.
  • an effector domain comprises a cytoplasmic portion that associates with a cytoplasmic signaling protein, wherein the cytoplasmic signaling protein is a lymphocyte receptor or signaling domain thereof, a protein comprising a plurality of ITAMs, a costimulatory factor, or any combination thereof.
  • intracellular signaling domains include the cytoplasmic sequences of the CD3 zeta chain, and/or co-receptors that act in concert to initiate signal transduction following CAR engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability.
  • an intracellular signaling domain of a CAR can be designed to comprise an intracellular signaling domain combined with any other desired cytoplasmic domain(s).
  • the intracellular signaling domain of a CAR can comprise an intracellular signaling domain and a costimulatory signaling region.
  • the costimulatory signaling region refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule.
  • a costimulatory molecule is a cell surface molecule other than the expressed marker ligand that is required for a response of lymphocytes to a marker.
  • examples of such molecules include CD27, CD28, 4-1BB (CD 137), OX40, CD30, CD40, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83.
  • CAR polynucleotides can comprise a sequence encoding for a spacer region.
  • the length of the spacer region can be customized for individual markers on targets to optimize target recognition and destruction or protection.
  • a spacer length can be selected based upon the location of a marker epitope, affinity of an antibody for the epitope, and/or the ability of the lymphocytes expressing the CAR to proliferate in vitro and/or in vivo in response to marker recognition.
  • a spacer region is found between the binding domain and a transmembrane domain of the CAR. Spacer regions can provide for flexibility of the binding domain and allows for high expression levels in the modified cells.
  • a spacer region can have at least 10 to 250 amino acids, at least 10 to 200 amino acids, at least 10 to 150 amino acids, at least 10 to 100 amino acids, at least 10 to 50 amino acids or at least 10 to 25 amino acids and including any integer between the endpoints of any of the listed ranges.
  • a spacer region has 250 amino acids or less; 200 amino acids or less, 150 amino acids or less; 100 amino acids or less; 50 amino acids or less; 40 amino acids or less; 30 amino acids or less; 20 amino acids or less; or 10 amino acids or less.
  • spacer regions can be derived from a hinge region of an immunoglobulin like molecule, for example all or a portion of the hinge region from a human IgG1, human IgG2, a human IgG3, or a human IgG4. Hinge regions can be modified to avoid undesirable structural interactions such as dimerization. In some embodiments, all or a portion of a hinge region can be combined with one or more domains of a constant region of an immunoglobulin. For example, a portion of a hinge region can be combined with all or a portion of a CH2 or CH3 domain or variant thereof.
  • CARs disclosed herein can also include transmembrane domains.
  • the CAR polynucleotide encodes the transmembrane domain.
  • the transmembrane domain provides for anchoring of the CAR in the lymphocyte membrane.
  • the transmembrane domain may be derived either from a natural or a synthetic source. When the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.
  • Transmembrane regions comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3, CD45, CD4, CDS, CD9, CDI6, CD22; CD33, CD37, CD64, CD80, CD86, CDl34, CDl37 and CD154.
  • synthetic or variant transmembrane domains comprise predominantly hydrophobic residues such as leucine and valine.
  • the CAR comprises a P28z fusion receptor composed of a single-chain antibody (scFv) specific for the extracellular domain of PSMA (J591) combined with CD28 and CD3 ⁇ cytoplasmic signaling domains.
  • the CAR comprises a P28z CAR of SEQ ID NO. 94.
  • SEQ ID NO. 94 includes murine components and was utilized in studies described herein. Amino acid positions 1-797 include the anti-PSMA scFv (J592) whereas positions 797-1477 include the murine CD8 transmembrane domain, murine CD28 signaling domain and the murine CD3zeta signaling domain. Any P28z domain can be individually replaced with optimized domains.
  • the transmembrane domain and signaling domains within positions 797-1477 of SEQ ID NO. 94 can be particularly replaced with domains optimized for use in humans or other animals.
  • any whole or portion of a binding domain, any whole or portion of an effector domain, any whole or portion of a spacer domain and/or any whole or portion of a transmembrane domain can be optimized for use in humans or other animals.
  • the P28z CAR is optimized for use in humans. When optimized for humans, the P28z CAR can have lowered or no immunogenicity in humans and have a lower number of non-immunogenic epitopes compared to non-human antibodies.
  • endosomal release agents include any compound or peptide sequence that facilitates cargo exit from the endosome of a lymphocyte.
  • exemplary endosomal release agents include imidazoles, poly or oligoimidazoles, PEIs, peptides, fusogenic peptides, polycarboxylates, polycations, masked oligo or poly cations or anions, acetals, polyacetals, ketals/polyketyals, orthoesters, polymers with masked or unmasked cationic or anionic charges, amphiphilic block copolymers and dendrimers with masked or unmasked cationic or anionic charges.
  • H5WYG peptide can be used to induce the lysis of membranes at low pH.
  • the histidine-rich peptide H5WYG is a derivative of the N-terminal sequence of the HA-2 subunit of the influenza virus hemagglutinin in which 5 of the amino acids have been replaced with histidine residues.
  • H5WYG is able to selectively destabilize membranes at a slightly acidic pH as the histidine residues are protonated.
  • the E1 protein from Semliki Forrest virus is also a useful endosomal release agent.
  • endosomal release agents include a hydrophobic membrane translocation sequence (MTS).
  • MTS hydrophobic membrane translocation sequence
  • An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO. 29).
  • An RFGF analogue e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO. 30)
  • a hydrophobic MTS can also be used.
  • Additional exemplary endosomal release agents include:
  • NLS Nuclear Localization Signals.
  • NLS nuclear localization signals
  • NLS are a class of short amino acid sequences from 3 to 100 amino acids in length, from 3 to 50, 4 to 30, or 4 to 20 amino acids in length.
  • Exemplary NLS sequences include (i) monopartite NLS exemplified by the SV40 large T antigen NLS (PKKKRKV) (SEQ ID NO: 51); (ii) bipartite NLS consisting of two basic domains separated by a variable number of spacer amino acids and exemplified by the Xenopus nucleoplasmin NLS (KRXXXXXXXXXKKKL) (SEQ ID NO: 52); and (iii) noncanonical sequences such as M9 of the hnRNP A1 protein, the influenza virus nucleoprotein NLS, and the yeast Ga14 protein NLS (Dingwall and Laskey, Trends Biochem Sci 16:478-481, 1991).
  • the NLS can be a highly cationic or basic peptide.
  • the NLS comprises two or more Arg or Lys amino acid residues.
  • the NLS can bind cytosolic proteins, such as importins and karyopherins, which recognize and transport NLS-containing sequences to the nuclear pore complex.
  • polynucleotides in one embodiment nanoparticle-encapsulated plasmids
  • SV40 T-Ag-derived NLS peptides include: PKKKRKV (SEQ ID NO. 51); PKKKRMV (SEQ ID NO. 53); PKKKRKVEDP (SEQ ID NO. 54); PKKGSKKA (SEQ ID NO. 55); PKTKRKV (SEQ ID NO. 56); CGGPKKKRKVG (SEQ ID NO. 57); PKKKIKV (SEQ ID NO. 58); CYDDEATADSQHSTPPKKKRKVEDPKDFESELLS (SEQ ID NO. 59); and CGYGPKKKRKVGG (SEQ ID NO. 60).
  • Additional exemplary NLS sequences include:
  • NLS NLS are also described in Cokol et al., 2000, EMBO Reports, 1(5):411-415; Boulikas, 1993, Crit. Rev. Eukaryot. Gene Expr., 3:193-227; Collas et al., 1996, Transgenic Research, 5: 451-458; Collas and Alestrom, 1997, Biochem. Cell Biol. 75: 633-640; Collas and Alestrom, 1998, Transgenic Research, 7: 303-309; Collas and Alestrom, 1996, Mol. Reprod. Devel., 45:431-438, and U.S. Pat. Nos. 7,531,624; 7,498,177; 7,332,586; and 7,550,650.
  • Nanocarriers Compositions disclosed herein include nanocarriers.
  • Nanocarriers can include a porous nanoparticle at least substantially covered by a coating.
  • polynucleotides and optionally NLSs can be found within the porous nanoparticle whereas optional lymphocyte-directing agents and endosomal release agents can be anchored to the coating.
  • Porous Nanoparticles can be constructed from any material capable of forming a porous network.
  • Exemplary materials include a variety of material including, without limitation, biocompatible polymers, metals, transition metals and metalloids.
  • Exemplary biocompatible polymers include, but not limited to, agar, agarose, alginate, alginate/calcium phosphate cement (CPC), beta-galactosidase ( ⁇ -GAL), (1,2,3,4,6-pentaacetyl a-D-galactose), cellulose, chitin, chitosan, collagen, elastin, gelatin, hyaluronic acid collagen, hydroxyapatite, poly(3-hydroxybutyrate-co-3-hydroxy-hexanoate) (PHBHHx), poly(lactide), poly(caprolactone) (PCL), poly(lactide-co-glycolide) (PLG), poly(Iactic-co-glycolic acid
  • Blending different polymer types in different ratios using various grades can result in characteristics that borrow from each of the contributing polymers.
  • Various terminal group chemistries can also be adopted.
  • Exemplary metals, transition metals and metalloids include lithium, magnesium, zinc, aluminum and silica.
  • the porous nanoparticles comprise silica.
  • the exceptionally high surface area of mesoporous silica (exceeding 1,000 m 2 /g) enables polynucleotide loading at levels exceeding conventional DNA carriers such as liposomes or polymer conjugates.
  • pores range in size from 10-20 nm.
  • Useful nanocarriers of particular embodiments also include those based on (i) lipid-based delivery systems, including cationic lipids, ionizable cationic lipids, lipid-like molecules and pH-sensitive amphiphiles; and/or (ii) polymeric RNA/DNA delivery systems such as polyethyleniminie (PEI)-based polymeric vectors, chitosan-based vectors, dendrimers (highly branched, spherical macromolecules synthesized from poly-amidoamine (PAMAM) and poly-propylene iminie (PPI), and block copolymers such as PAA/BMA/DMAEMA and PDMAEMA.
  • PEI polyethyleniminie
  • PAMAM poly-amidoamine
  • PPI poly-propylene iminie
  • block copolymers such as PAA/BMA/DMAEMA and PDMAEMA.
  • the porous nanoparticles can be a variety of different shapes, including spheroidal, cuboidal, pyramidal, oblong, cylindrical, toroidal, and the like.
  • the polynucleotides can be included in the porous nanoparticles in a variety of ways.
  • the polynucleotides can be encapsulated in the porous nanoparticles.
  • the polynucleotides can be associated (e.g., covalently and/or non-covalently) with the surface or close underlying vicinity of the surface of the porous nanoparticles.
  • the polynucleotides can be incorporated in the porous nanoparticles e.g., integrated in the material of the porous nanoparticles.
  • the polynucleotides can be incorporated into a polymer matrix of polymer nanoparticles.
  • One of ordinary skill in the art will appreciate the various ways to carry the polynucleotides so as to allow delivery of the polynucleotide molecules to the lymphocytes.
  • porous nanoparticles include liposomes.
  • Liposomes are microscopic vesicles consisting of at least one concentric lipid bilayer. Vesicle-forming lipids are selected to achieve a specified degree of fluidity or rigidity of the final complex.
  • liposomes provide a lipid composition that is an outer layer surrounding a porous nanoparticle.
  • Liposomes can be neutral (cholesterol) or bipolar and include phospholipids, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and sphingomyelin (SM) and other type of bipolar lipids including but not limited to dioleoylphosphatidylethanolamine (DOPE), with a hydrocarbon chain length in the range of 14-22, and saturated or with one or more double C ⁇ C bonds.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • PI phosphatidylinositol
  • SM sphingomyelin
  • DOPE dioleoylphosphatidylethanolamine
  • lipids capable of producing a stable liposome are phospholipids, such as hydrogenated soy phosphatidylcholine (HSPC), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebro sides, distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE) and dioleoylphosphatidylethanolamine 4-(N-maleimido-methyl)cyclohexane-1
  • HSPC hydrogenated soy phosphati
  • Additional non-phosphorous containing lipids that can become incorporated into liposomes include stearylamine, dodecylamine, hexadecylamine, isopropyl myristate, triethanolamine-lauryl sulfate, alkyl-aryl sulfate, acetyl palmitate, glycerol ricinoleate, hexadecyl stereate, amphoteric acrylic polymers, polyethyloxylated fatty acid amides, and the cationic lipids mentioned above (DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol).
  • DDAB DODAC
  • DMRIE DMTAP
  • DOGS DOGS
  • DOTAP DOTMA
  • DOSPA DPTAP
  • DSTAP DC-Chol
  • Negatively charged lipids include phosphatidic acid (PA), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol and (DOPG), dicetylphosphate that are able to form vesicles.
  • lipids used to create liposomes disclosed herein include cholesterol, hydrogenated soy phosphatidylcholine (HSPC) and, the derivatized vesicle-forming lipid PEG-DSPE.
  • the size of the nanocarriers can vary over a wide range and can be measured in different ways.
  • the nanocarriers of the present disclosure can have a minimum dimension of 100 nm.
  • the nanocarriers of the present disclosure can also have a minimum dimension of equal to or less than 500 nm, less than 150 nm, less than 100 nm, less than 90 nm, less than 80 nm, less than 70 nm, less than 60 nm, less than 50 nm, less than 40 nm, less than 30 nm, less than 20 nm, or less than 10 nm.
  • the nanocarriers can have a minimum dimension ranging between 5 nm and 500 nm, between 10 nm and 100 nm, between 20 nm and 90 nm, between 30 nm and 80 nm, between 40 nm and 70 nm, and between 40 nm and 60 nm.
  • the dimension is the diameter of nanoparticles or coated nanoparticles.
  • a population of nanocarriers of the present disclosure can have a mean minimum dimension of equal to or less than 500 nm, less than 100 nm, less than 90 nm, less than 80 nm, less than 70 nm, less than 60 nm, less than 50 nm, less than 40 nm, less than 30 nm, less than 20 nm, or less than 10 nm.
  • a population of nanocarriers in a composition of the present disclosure can have a mean diameter ranging between 5 nm and 500 nm, between 10 nm and 100 nm, between 20 nm and 90 nm, between 30 nm and 80 nm, between 40 nm and 70 nm, and between 40 nm and 60 nm.
  • Dimensions of the nanocarriers can be determined using, e.g., conventional techniques, such as dynamic lightscattering and/or electron microscopy.
  • the compositions include protocells as nanocarriers.
  • Protocells can be formed via fusion of liposomes to porous silica nanoparticles.
  • the high pore volume and surface area of the spherical mesoporous silica core allow high-capacity encapsulation of a spectrum of cargos, including plasmid DNA.
  • the supported lipid bilayer whose composition can be modified for specific biological applications, can serve as a modular, reconfigurable scaffold, allowing the attachment of a variety of molecules, such as lymphocyte-directing agents, to provide cell-specific targeting and controlled intracellular trafficking.
  • protocells can efficiently introduce polynucleotides into lymphocytes.
  • anti-CD3 antibodies can be coupled onto protocell nanocarriers to selectively target the nanocarriers to T cells for rapid receptor-induced endocytosis.
  • Protocells can be formed via fusion of liposomes with porous silica nanoparticles ( FIGS. 2A , B).
  • the high pore volume and surface area of the spherical mesoporous silica core allow high-capacity encapsulation of a spectrum of cargos, including plasmid DNA.
  • the membrane serves as a modular scaffold for the attachment of a variety of targeting moieties. In the embodiment depicted in FIG.
  • the pH-sensitive fusogenic peptide H5WYG is tethered to the nanocarrier surface to facilitate endosomal escape.
  • the plasmid DNA was also modified before encapsulation into nanoparticles with the SV40 large T antigen nuclear localization signal peptide ( FIG. 2A ).
  • compositions comprising, consist of or consist essentially of the nanoparticles, porous nanoparticles and/or nanocarriers.
  • active ingredients can be provided as part of compositions that comprise, consist of or consist essentially of the nanoparticles, porous nanoparticles and/or nanocarriers.
  • the compositions can be formulated for administration to subjects.
  • the active ingredients are provided as part of a composition that can comprise, for example, at least 0.1% w/v of active ingredient(s); at least 1% w/v of active ingredient(s); at least 10% w/v of active ingredient(s); at least 20% w/v of active ingredient(s); at least 30% w/v of active ingredient(s); at least 40% w/v of active ingredient(s); at least 50% w/v of active ingredient(s); at least 60% w/v of active ingredient(s); at least 70% w/v of active ingredient(s); at least 80% w/v of active ingredient(s); at least 90% w/v of active ingredient(s); at least 95% w/v of active ingredient(s); or at least 99% w/v of active ingredient(s).
  • the active ingredients are provided as part of a composition that can comprise, for example, at least 0.1% w/w of active ingredient(s); at least 1% w/w of active ingredient(s); at least 10% w/w of active ingredient(s); at least 20% w/w of active ingredient(s); at least 30% w/w of active ingredient(s); at least 40% w/w of active ingredient(s); at least 50% w/w of active ingredient(s); at least 60% w/w of active ingredient(s); at least 70% w/w of active ingredient(s); at least 80% w/w of active ingredient(s); at least 90% w/w of active ingredient(s); at least 95% w/w of active ingredient(s); or at least 99% w/w of active ingredient(s).
  • compositions disclosed herein can be formulated for administration by, without limitation, injection, inhalation, infusion, perfusion, lavage or ingestion.
  • the compositions disclosed herein can further be formulated for, without limitation, intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral and/or subcutaneous administration and more particularly by intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral and/or subcutaneous injection.
  • compositions can be formulated as aqueous solutions, such as in buffers including Hanks' solution, Ringer's solution, or physiological saline.
  • aqueous solutions can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulation can be in lyophilized and/or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • compositions can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like.
  • suitable excipients include binders (gum tragacanth, acacia, cornstarch, gelatin), fillers such as sugars, e.g.
  • lactose sucrose, mannitol and sorbitol; dicalcium phosphate, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxy-methylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents.
  • disintegrating agents can be added, such as corn starch, potato starch, alginic acid, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • solid dosage forms can be sugar-coated or enteric-coated using standard techniques. Flavoring agents, such as peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. can also be used.
  • compositions can be formulated as aerosol sprays from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may
  • composition formulation disclosed herein can advantageously include any other pharmaceutically acceptable carriers which include those that do not produce significantly adverse, allergic or other untoward reactions that outweigh the benefit of administration, whether for research, prophylactic and/or therapeutic treatments.
  • exemplary pharmaceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990.
  • formulations can be prepared to meet sterility, pyrogenicity, general safety and purity standards as required by United States FDA Office of Biological Standards and/or other relevant foreign regulatory agencies.
  • Exemplary generally used pharmaceutically acceptable carriers include any and all bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, chelating agents (e.g., EDTA), gels, binders, disintegration agents, and/or lubricants.
  • bulking agents or fillers include any and all bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g., ascorbic acid, methionine, vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, chelating agents (e.g., EDTA), gels, binders, disintegration agents, and/or lubricants.
  • antioxidants e.g
  • Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers and/or trimethylamine salts.
  • Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3-pentanol.
  • Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol or mannitol.
  • Exemplary stabilizers include organic sugars, polyhydric sugar alcohols, polyethylene glycol; sulfur-containing reducing agents, amino acids, low molecular weight polypeptides, proteins, immunoglobulins, hydrophilic polymers or polysaccharides.
  • compositions can also be formulated as depot preparations.
  • Depot preparations can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salts.
  • compositions can be formulated as sustained-release systems utilizing semipermeable matrices of solid polymers containing at least one active ingredient.
  • sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release systems may, depending on their chemical nature, release active ingredients following administration for a few weeks up to over 100 days.
  • compositions can also include plasmid DNA carrying one or more anticancer genes selected from p53, RB, BRCA1, E1A, bcl-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , TNF- ⁇ and/or HSV-tk.
  • anticancer genes selected from p53, RB, BRCA1, E1A, bcl-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , TNF- ⁇ and/or HSV-tk.
  • Compositions can also include or be administered in combination with one or more antineoplastic drugs including adriamycin, angiostatin, azathioprine, bleomycin, busulfane, camptothecin, carboplatin, carmustine, chlorambucile, chlormethamine, chloroquinoxaline sulfonamide, cisplatin, cyclophosphamide, cycloplatam, cytarabine, dacarbazine, dactinomycin, daunorubicin, didox, doxorubicin, endostatin, enloplatin, estramustine, etoposide, extramustinephosphat, flucytosine, fluorodeoxyuridine, fluorouracil, gallium nitrate, hydroxyurea, idoxuridine, interferons, interleukins, leuprolide, lobaplatin, lomustine, mannomustine, mechlorethamine, mechlore
  • Methods disclosed herein include treating subjects (humans, veterinary animals, livestock and research animals) with compositions, active ingredients, nanoparticles, porous nanoparticles and/or nanocarriers disclosed herein. Treating subjects includes delivering a therapeutically effective amount.
  • An “effective amount” is the amount of a compound necessary to result in a desired physiological change in the subject. Effective amounts are often administered for research purposes. Effective amounts disclosed herein reduce the number of unwanted cell types in a subject.
  • a “prophylactic treatment” includes a treatment administered to a subject who does not display signs or symptoms of a disease or condition associated with or caused by a target or displays only early signs or symptoms of the disease or condition such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the disease or condition further.
  • a prophylactic treatment functions as a preventative treatment against a disease or disorder associated with or caused by a target.
  • a “therapeutic treatment” includes a treatment administered to a subject who displays symptoms or signs of a disease or condition associated with or caused by a target and is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of the disease or condition.
  • “Therapeutically effective amounts” include those that provide effective amounts, prophylactic treatment and/or therapeutic treatment. Therapeutically effective amounts need not fully prevent or cure the disease or condition but can also provide a partial benefit, such as reduction in the number of unwanted targets; reduction of destruction of wanted targets; and/or a delay of onset or alleviation or improvement of at least one symptom of the disease or condition.
  • effective amounts and therapeutically effective amounts can be initially estimated based on results from in vitro assays and/or animal model studies.
  • a dose can be formulated in animal models to achieve a circulating concentration range that includes an IC 50 as determined in cell culture against a particular target. Such information can be used to more accurately determine useful doses in subjects of interest.
  • the actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of condition, type of disease, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.
  • a dose can comprise 1 ⁇ g/kg, 5 ⁇ g/kg, 10 ⁇ g/kg, 15 ⁇ g/kg, 20 ⁇ g/kg, 25 ⁇ g/kg, 30 ⁇ g/kg, 35 ⁇ g/kg, 40 ⁇ g/kg, 45 ⁇ g/kg, 50 ⁇ g/kg, 55 ⁇ g/kg, 60 ⁇ g/kg, 65 ⁇ g/kg, 70 ⁇ g/kg, 75 ⁇ g/kg, 80 ⁇ g/kg, 85 ⁇ g/kg, 90 ⁇ g/kg, 95 ⁇ g/kg, 100 ⁇ g/kg, 150 ⁇ g/kg, 200 ⁇ g/kg, 250 ⁇ g/kg, 350 ⁇ g/kg, 400 ⁇ g/kg, 450 ⁇ g/kg, 500 ⁇ g/kg, 550 ⁇ g/kg, 600 ⁇ g/kg, 650
  • a dose can comprise 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, 1000 mg/kg or more.
  • Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or yearly.
  • a treatment regimen e.g., daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or yearly.
  • Exemplary methods disclosed herein include administering nanocarriers to a subject in need thereof.
  • the nanocarriers are directed to chosen lymphocytes in the subject and are designed to be internalized by the lymphocytes. Once internalized, the nanocarriers further deliver a polynucleotide having a sequence that encodes a targeting agent.
  • the polynucleotide modifies the lymphocytes to express the targeting agent, which subsequently binds a marker associated with the target.
  • the lymphocytes can kill or otherwise trigger the destruction of unwanted targets such as unwanted cells, thereby treating a disease or condition associated with the unwanted cell type.
  • the lymphocytes can protect wanted targets such as wanted cells, thereby treating a disease or condition associated with unwanted destruction of the wanted cell type.
  • nanocarriers can be loaded with polynucleotides (e.g., Transgenes) that encode for a defined tumor- or virus-specific TCR.
  • polynucleotides e.g., Transgenes
  • Surface-anchored lymphocyte-directing agents that recognize T-cell-specific proteins enable the nanocarriers to selectively bind T-cells.
  • the nanocarriers Upon infusion into a subject's bloodstream, the nanocarriers can deliver TCR genes into T-cells, which can subsequently express this TCR on their surface. Equipped with a therapeutically relevant TCR, the T-cells can recognize and lyse malignant cells or virus-infected cells or other targeted unwanted cell types.
  • NK cells are selectively modified to express CARs or high-affinity TCRs.
  • hematopoietic stem cells HSGs
  • monocytes/macrophages cells are selectively modified to express CARs or high-affinity ligands specific for viruses, bacteria, fungus or yeast antigens.
  • B cells are selectively modified to express tumor- or virus-specific antibodies.
  • T REG cells are selectively modified to express CARs or high-affinity ligands specific for autoimmune markers, allergic reaction markers or beneficial bacteria.
  • Additional embodiments include methods of delivering pre-designed synthetic nanocarriers to lymphocytes (e.g., T-cells), in which the nanocarriers can be loaded with polynucleotides (e.g., plasmids) that encode a receptor for an antigen (e.g., a prostate tumor-targeting receptor P28z). Internalization of the nanocarriers can render transfected lymphocytes (e.g., T-cells) capable of lysing cells associated with the antigen (e.g., a prostate tumor).
  • lymphocytes e.g., T-cells
  • the nanocarriers can be loaded with polynucleotides (e.g., plasmids) that encode a receptor for an antigen (e.g., a prostate tumor-targeting receptor P28z).
  • Internalization of the nanocarriers can render transfected lymphocytes (e.g., T-cells) capable of lysing cells associated with the antigen (e.
  • delivery of the nanocarriers including the receptor genes into lymphocytes can include, e.g., (1) specific binding to the lymphocytes (e.g., T-cells), (2) internalization of the nanocarriers by the lymphocytes, (3) escape from endocytic vesicles into the cytoplasm after internalization, (4) release of the polynucleotide, which (5) can be transported into the nucleus of the lymphocytes and (6) transcribed to deliver genes for expressing a receptor for the antigen.
  • lymphocytes e.g., T-cells
  • delivery of the nanocarriers including the receptor genes into lymphocytes can include, e.g., (1) specific binding to the lymphocytes (e.g., T-cells), (2) internalization of the nanocarriers by the lymphocytes, (3) escape from endocytic vesicles into the cytoplasm after internalization, (4) release of the polynucleotide, which (5) can be transported into the nucleus of the lymphocyte
  • the methods are used to target unwanted cancer cells.
  • the disclosed methods provide a new paradigm for the treatment of cancer that can involve programming circulating lymphocytes with tumor-recognizing capabilities in vivo.
  • This paradigm contrasts with those currently used to generate T cells with defined anti-cancer specificities, which involve isolation of the lymphocytes from the patient and genetically modifying them in the laboratory with tumor antigen-specific receptors using retroviral or lentiviral vectors; the programmed cells are then expanded and infused back into the patient where they can recognize and destroy cancer cells.
  • This ex vivo production of modified cells requires the production of a new lymphocyte cohort for each patient, a laborious process that can only be accomplished at elaborate cell-production facilities available at just a few cancer centers worldwide.
  • compositions and methods disclosed herein can produce targeting effects within a subject's circulatory system in only days.
  • the disclosed methods provide the first implementation of nanocarriers for the genetic engineering of immune cells to selectively target cells associated with markers for various therapeutic objectives. For example, and in relation to cancer cells as an unwanted cell type, previous nanotechnology-based clinical research has focused on particles that selectively accumulate chemotherapeutics, siRNA, or imaging agents at tumor sites while minimizing off-target toxicities.
  • the methods described herein are different: instead of introducing therapeutics into tumor tissue, the disclosed methods introduce genes encoding tumor-recognizing receptors into circulating lymphocytes, which in turn bind and destroy tumor cells. This strategy has the advantage that, unlike agent-loaded nanoparticles (which are quickly cleared by phagocytes), the modified lymphocytes can persist and proliferate in the subject for a long-term effect.
  • the current disclosure provides a new, more effective therapy.
  • the disclosure shifts the focus from broad-impact chemotherapy or radiotherapy (which have many negative side-effects) to tumor-specific immunotherapeutics (which do not harm healthy tissue).
  • Nanoparticle gene therapy will provide clinicians with the ability to instantly treat diagnosed patients with an off-the shelf composition that can be widely distributed at low cost, and is amenable to changes in dose and specificity as the treatment evolves.
  • therapeutically effective amounts can decrease the number of tumor cells, decrease the number of metastases, decrease tumor volume, increase life expectancy, induce apoptosis of cancer cells, induce cancer cell death, induce chemo- or radiosensitivity in cancer cells, inhibit angiogenesis near cancer cells, inhibit cancer cell proliferation, inhibit tumor growth, prevent metastasis, prolong a subject's life, reduce cancer-associated pain, reduce the number of metastases, and/or reduce relapse or re-occurrence of the cancer following treatment.
  • the methods can include obtaining lymphocytes from a subject.
  • Lymphocytes can, e.g., be obtained from a subject using any procedure generally known in the art.
  • blood can be obtained from a subject and lymphocytes can be isolated.
  • the isolated lymphocytes can then be combined with nanocarriers (or a composition comprising nanocarriers) including a polynucleotide having a sequence that encodes a targeting agent.
  • the nanocarriers can be internalized by the lymphocytes such that the lymphocytes then incorporate the polynucleotide and express the targeting agent.
  • the modified lymphocytes expressing the targeting agent can be administered to the subject such that, after the administering, the lymphocytes bind to the targeted markers on cells associated with the disease, thereby treating the disease.
  • the modifying of the lymphocytes can be fully accomplished ex vivo prior to administration, and/or nanocarriers can be internalized and the lymphocytes can be administered to the subject while modifying is being carried out leading to expression of the targeting agents.
  • Each of the exemplary embodiments in Set 1 and Set 2 also includes an embodiment wherein the lymphocyte-directing agent can be removed. These embodiments are especially useful when the selected cell types are monocytes/macrophages and broad non-specific uptake of the nanocarriers can be expected.
  • FIG. 2A Lipid nanoparticles ( FIG. 2A ) were loaded with a minicircle gene ( FIG. 3 ) encoding the chimeric antigen receptor P28z.
  • P28z is a fusion receptor composed of a single-chain antibody (scFv) specific for the extracellular domain of PSMA (J591) combined with CD28 and CD3 cytoplasmic signaling domains ( FIG. 4A ; SEQ ID NO. 94).
  • chimeric antigen receptors are fusion receptors including an antigen-binding domain, a transmembrane domain and an intracellular signaling domain resulting in T-cell activation after antigen binding.
  • the P28z CAR directs T-cells toward the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells. Therefore, the introduction of the P28z gene into T-cells renders them capable of recognizing and lysing prostate tumor.
  • PSMA prostate-specific membrane antigen
  • the P28z gene was cloned under the control of the T-cell specific promoter CD3 delta into a minicircle plasmid. Minicircles can include episomal DNA vectors that are produced as circular expression cassettes devoid of any bacterial plasmid DNA backbone. Their smaller molecular size can enable more efficient transfections and offers sustained expression over a period of weeks as compared to standard plasmid vectors that only work for a few days.
  • the minicircle plasmid DNA was entrapped into nanocarriers.
  • DOPC, DOPE, cholesterol, and 18:1 PEG 2000 PE lipids were first mixed in a 55:5:30:10 mass ratio, dried under a stream of nitrogen, and placed in a vacuum oven overnight to remove residual chloroform.
  • the lipid film was then dissolved in tert-butanol and mixed 1:1 (v/v) with a P28z minicircle plasmid solution (diluted in 10 mM Tris-HCl (pH 7.4) with 0.85% (w/v) NaCl and 0.25 M sucrose) such that the final DOPC:DNA ratio was 10:1 (w/w).
  • the mixture was vortexed and passed through a 100 nm filter at least 10 times using a Mini-Extruder set (Avanti Polar Lipids, Inc.; Alabaster, Al., USA).
  • anti-mouse CD8 antibodies were coupled to the surface of the lipid envelope.
  • Anti-CD8 antibodies (10 mg/ml) were mildly reduced with a 25 ⁇ molar excess of DTT for 20 min at 25° C. in the presence of 10 mM EDTA in PBS to expose free hinge region thiols.
  • DTT antibodies were passed through a desalting column.
  • the heterobifunctional cross-linker SM(PEG) 24 was used to anchor antibodies to the surface of DNA-loaded liposomes (Amine groups are present in the head groups of PE lipids, free thiol groups on antibodies were created by DTT, SM(PEG) 24 cross-links between amines and thiol groups).
  • Liposomes were first incubated with a tenfold molar excess of SM(PEG) 24 for 2 h at room temperature and centrifuged to remove unreacted cross-linker. Activated liposomes were then incubated with a fivefold molar excess of reduced anti-CD8 antibody for 2 h at room temperature. Unbound antibody was removed using a centrifugal filtration device (10 kDa MWCO). The final liposome used for subsequent experiments were ⁇ 100 nm in diameter.
  • P28z gene transfer into T-cells using targeted DNA nanocarriers renders them capable of lysing prostate tumor.
  • the transfection efficiency of liposome-mediated gene transfer into primary T-cells was assessed. 60 ⁇ 10 6 mouse effector CD8 + T-cells mL ⁇ 1 were resuspended in RPMI medium and an equal volume of lipid nanoparticles (loaded with P28z minicircle DNA) were added with a 100 particles/T-cell ratio. Cells were incubated at 37° C. for 30 min with gentle agitation every 10 min and unbound particles were removed by a PBS wash. Two days later, the percentage of T-cells expressing the P28z CAR was determined by flow cytometry.
  • Nanoparticle-transfected T cells were functional, selectively lysing PSMA-expressing TRAMP prostate tumor cells ( FIGS. 4C ,D).
  • CD3-targeted protocell nanoparticles selectively bind circulating T cells in mice.
  • a goal of the current disclosure is to selectively and quickly edit lymphocyte specificity in vivo to target unwanted cells.
  • mice were systemically injected with 1 ⁇ 10 11 fluorescently tagged nanoparticles. After 6 hours peripheral blood was collected by retro-orbital puncture and the percentage of fluorescent T cells was quantified by flow cytometry.
  • CD3-targeted protocells labeled the majority of T cells in the blood, with relatively low binding to off-target cells ( FIG. 4E , left panel). Confocal imaging of sorted T cells showed that nanoparticles are rapidly internalized from the cell surface into the cytoplasm as a result of receptor-induced endocytosis ( FIG. 4E , right panel).
  • TRAMP transgenic mice spontaneously develop orthotopic prostate tumors following puberty.
  • TRAMP tumors do not express significant amounts of PSMA, a target in experiments using the P28z CAR.
  • longitudinal studies to measure the prostate cancer volume in TRAMP animals rely on expensive and time-consuming magnetic resonance imaging (MRI) techniques, which preclude analysis of large cohorts of mice.
  • MRI magnetic resonance imaging
  • FLuc Firefly luciferase
  • TRAMP-PSMA-FLuc tumor cells Following orthotopic transplantation into the dorsal lobe of the prostate gland of C57BL/6 mice, TRAMP-PSMA-FLuc tumor cells reproducibly developed into lesions within three weeks, with all animals displaying progressive metastatic tumor spread to regional (pelvic, paraaortic) lymph nodes ( FIG. 5 ).
  • the data shown in FIGS. 2 and 4 establish the ability to generate nanoparticles that efficiently program T cells with genes encoding receptors specific for prostate tumor. While this strategy rapidly generates tumor-reactive T cells, expression of transgenes is transient because transferred plasmids are diluted out every time the lymphocyte divides.
  • the current example evaluates persistent receptor gene expression in actively dividing T cells caused by inserting into the plasmid either: 1) a scaffold/matrix attachment region (S/MAR) sequence (which can undergo episomal self-replication), or 2) a transposable piggyBac element (which integrates the transgene into the genome). Stable and dependable transgene expression in dividing T cells will allow nanoparticle-transfected lymphocytes to serially kill unwanted cell types providing long-lived immunity against such cells.
  • S/MAR scaffold/matrix attachment region
  • a S/MAR sequence (provided by Dr. Lipps, University Witten/Herdecke) or piggyBac inverted terminal repeats (provided by Dr. Craig, Johns Hopkins University) will be cloned into minicircle plasmids that encode the P28z receptor, as illustrated in FIG. 6 .
  • Protocell nanoparticles loaded with equivalent amounts of P28z, P28z-S/MAR, or P28z-piggyBac minicircle DNA will be incubated with mouse CD8 + T lymphocytes at a cell:particle ratio of 1:10. Following nanoparticle transfection, T cells will be expanded with plate-bound anti-CD3/anti-CD28 antibodies. Flow cytometry will be used to assess P28z receptor expression levels and persistence in proliferating T cells every 24 hours during a two week culture period.
  • Southern blot analysis will be performed by digesting isolated DNA with Not1. This restriction site is present only once in the P28z minicircle episome; it yields a 2.8-kb band for the extrachromosomal episome but yields fragments of various lengths for plasmids integrated into the genome.
  • S/MAR-based episomes and piggyBac transposons are two highly efficient tools to modify cells to achieve stable gene expression.
  • Incorporating S/MAR sequences or piggyBac transposable elements into nanocarrier-delivered plasmids will also maintain high-level P28z gene expression in T cells over weeks as a result of episomal self-replication or somatic integration, respectively. Because plasmids containing S/MAR elements do not integrate into the host genome, P28z gene expression is independent of chromosomal position effects and therefore not subject to epigenetic silencing and cis-acting sequences.
  • This Example determines that systemic injections of DNA nanocarriers can program sufficient quantities of T cells to target and eliminate disseminated prostate cancer.
  • the tests will be conducted using nanoparticles loaded with minicircle DNA encoding the P28z CAR (described above), to generate PSMA-specific lymphocytes.
  • the results of the studies will be positive following testing of the following questions: (1) how many peripheral T cells are genetically modified to express P28z following a single intravenous dose of CD3-targeting nanoparticles loaded with genes encoding the receptor?; (2) do the injected nanoparticles selectively edit the antigen-specificity of peripheral T cells without affecting off-target cells? And (3) what nanoparticle dosage is required to bring about T cell-mediated regression of metastatic prostate tumors in mice?
  • peripheral T cells are modified by nanoparticle gene therapy?
  • the goal of this study is to edit the antigen specificity of at least 10% of peripheral T cells within five days following a single bolus injection of nanocarriers.
  • some of the strongest vaccine vectors reported in the literature induce frequencies of self/tumor antigen-specific T cells of 1-4% following repeated immunizations over weeks.
  • Mice will be systemically injected with 1 ⁇ 10 9 , 1 ⁇ 10 10 , or 1 ⁇ 10 11 nanocarriers loaded with minicircle DNA encoding P28z, or with GFP as a control.
  • the percentage of P28z + T cells will be quantified by flow cytometry using fluorescent recombinant PSMA protein as the reporter, as performed in previous gene transfer studies (see, e.g., FIG. 4B ).
  • the other cell types will be identified using the following reporters: anti-CD8 and anti-CD4 (T-cell markers), anti-B220 (B-cell marker), anti-NK1.1 (NK-cell marker), anti-CD115, anti-F4/80 and anti-CD11b (monocyte markers), anti-Ly6G and anti-CD11 b (neutrophil markers), and anti-Gr-1 antibody (granulocyte marker).
  • nanocarrier injections To develop a reproducibly effective treatment for metastatic prostate cancer, the therapeutically optimal frequency and dosage of nanocarrier injections must be determined.
  • a test system will be created by injecting luciferase-expressing TRAMP-PSMA tumor cells into the prostate of C57BL/6 mice and allowing them to develop for three weeks before performing the tests (see, e.g., FIG. 5 ).
  • mice will be systemically injected with CD3-targeting nanocarriers carrying P28z-encoding transgenes, according to four administration protocols: single high-dose bolus injection (1 ⁇ 10 10 nanoparticles, i.v.); high-frequency high-dose injections (1 ⁇ 10 10 nanoparticles, i.v. every 3 days for 30 days); single low-dose injection (1 ⁇ 10 9 nanoparticles, i.v.); or high-frequency low-dose injections (1 ⁇ 10 9 nanoparticles, i.v. every 3 days for 30 days).
  • mice To compare the therapeutic efficacy of nanoparticle infusions with conventional adoptive T-cell therapy, one additional group of mice will be treated with a single dose of 10 million T cells transduced ex vivo with P28z-encoding retroviral vectors. Differences in TRAMP-PSMA tumor progression will be measured between treatment and control groups using bioluminescence imaging. To correlate tumor regression with the concentration of nanoparticle-programmed T cells in the peripheral circulation, the percentage of P28z + T cells in whole blood will be quantified by flow cytometry every 6 days.
  • circulating T cells can be selectively programmed to target prostate tumors without genetically modifying other cells.
  • This specificity can be achieved by coating the nanoparticles with CD3-recognizing antibodies, and by expressing the P28z transgene under the control of the T cell-specific CD3 delta promoter. If flow cytometry shows that more than 20% of P28z-expressing cells in the peripheral blood are not the targeted T cells, the density of anti-CD3 antibodies on the surface of nanocarriers will be increased to improve T cell targeting. If the CD3 delta promoter is too weak to mediate sufficient levels of receptor gene expression in vivo, the murine stem cell leukemia virus (MSCV) promoter can be used to express the P28z CAR in T cells. The MSCV promoter exhibits strong activity in hematopoietic cells and stem cells.
  • Example 7 determines that nanocarriers can alternatively modify host T cells with prostate tumor-specific T-cell receptor (TCR) genes that target different antigens.
  • TCR tumor-specific T-cell receptor
  • MHC major histocompatibility complex
  • WT1 A murine receptor (3D TCR) that has a high affinity for the intracellular oncoprotein Wilms tumor 1 (WT1) has been successfully engineered by a team of immunologists led by P. Greenberg at the Fred Hutchinson Cancer Research Center. WT1 was ranked first in a list of 75 cancer antigens in a recent National Cancer Institute prioritization project. It is strongly expressed in high-grade prostate tumor where it promotes the formation of metastases, but is absent in non-neoplastic or benign prostatic hyperplasia tissues. In line with these studies, high WT1 gene expression was detected in the TRAMP prostate tumor cells used herein. WT1 is detected at only very low levels in other normal tissues, particularly hematopoietic stem cells and kidney podocytes.
  • T cells have been shown to be capable of selectively recognizing transformed cells expressing high levels without toxicity to normal tissues.
  • Example 7 it will be shown that systemic injections of protocells loaded with genes encoding affinity-matured WT1-specific TCRs can impart specificity for WT1 to host T cells and lead to elimination of prostate cancer.
  • mice will be injected with 1 ⁇ 10 10 nanoparticles carrying 3D TCR genes. Control nanoparticles will be loaded with GFP-expressing plasmids. Peripheral blood collected by retro-orbital puncture every four days over a 12-day period will be used to quantify WT1-TCR + T cells and other leukocyte subsets by flow cytometry using a fluorescent conjugate of the WT1-derived RMFPNAPYL epitope tetramer as the reporter.
  • luciferase-expressing TRAMP tumors will be implanted into the prostate of C57BL/6 mice. Three weeks later, animals will be treated with: a single high-dose bolus injection (1 ⁇ 10 10 nanoparticles i.v.); high-frequency high-dose injections (1 ⁇ 10 10 nanoparticles i.v. every 3 days for 30 days); a single low-dose injection (1 ⁇ 10 9 nanoparticles, i.v.); or high-frequency low-dose injections (1 ⁇ 10 9 nanoparticles, i.v. every 3 days for 30 days).
  • mice will be injected with 10 million T cells, which were ex vivo transduced with 3D TCR genes using retroviral vectors. Differences in TRAMP prostate tumor regression between treatment and control groups will be measured using bioluminescence imaging.
  • T cell responses in antitumor immunity can be decisively dependent on the quality of the TCRs involved. Due to thymic selection, the affinities of natural TCRs that target oncogenic self-proteins like WT1 are generally much lower than those of typical virus-targeting TCRs. However, the ability of a naturally occurring TCR to recognize antigens like WT1 can be markedly enhanced by in vitro affinity maturation. Based on these data, if genes for an affinity-optimized, WT1-specific TCR are introduced into circulating T cells using the disclosed nanoparticle gene therapy approach, T cells will effectively recognize and kill prostate cancer cells.
  • 3D TCRs are fully functional in CD4 + and CD8 + T cells, and CD4 + T cells can directly mediate tumor destruction and/or provide cytokine help for CD8 + T cells; however, tumor-specific CD4 + regulatory T cells abrogate CD8 T cell-mediated tumor rejection. If CD3-targeted nanoparticles generate undesirable WT1-specific CD4 + regulatory T cells, nanoparticles can be targeted to CD8 + T cells only. These studies will demonstrate that nanoparticles can deliver rationally engineered TCR genes into host T-cells and enable them to recognize intracellular tumor-associated antigen.
  • HIV-infected humanized NOD/shi-scid/ ⁇ c null (NOG) mice with nanoparticles carrying HIV-gag protein-specific TCR transgenes, or with control plasmids expressing green fluorescent protein will be studied. Differences in HIV viral titers between treatment groups will be determined and administration of the nanoparticles will show a beneficial result.
  • NOG humanized NOD/shi-scid/ ⁇ c null
  • Sequence information provided by public database can be used to identify nucleic acid sequences encoding peptides disclosed herein and vice versa. Variants of the sequences disclosed and referenced herein are also included.
  • Variants of peptides can include those having one or more conservative amino acid substitutions.
  • a “conservative substitution” involves a substitution found in one of the following conservative substitutions groups: Group 1: Alanine (Ala), Glycine (Gly), Serine (Ser), Threonine (Thr); Group 2: Aspartic acid (Asp), Glutamic acid (Glu); Group 3: Asparagine (Asn), Glutamine (Gin); Group 4: Arginine (Arg), Lysine (Lys), Histidine (His); Group 5: Isoleucine (Ile), Leucine (Leu), Methionine (Met), Valine (Val); and Group 6: Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp).
  • amino acids can be grouped into conservative substitution groups by similar function or chemical structure or composition (e.g., acidic, basic, aliphatic, aromatic, sulfur-containing).
  • an aliphatic grouping may include, for purposes of substitution, Gly, Ala, Val, Leu, and Ile.
  • Other groups containing amino acids that are considered conservative substitutions for one another include: sulfur-containing: Met and Cysteine (Cys); acidic: Asp, Glu, Asn, and Gin; small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gin; polar, positively charged residues: His, Arg, and Lys; large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information is found in Creighton (1984) Proteins, W.H. Freeman and Company.
  • Variants of the protein and nucleic acid sequences disclosed or referenced herein also include sequences with at least 70% sequence identity, 80% sequence identity, 85% sequence, 90% sequence identity, 95% sequence identity, 96% sequence identity, 97% sequence identity, 98% sequence identity, or 99% sequence identity to he protein and nucleic acid sequences disclosed or referenced herein.
  • % sequence identity refers to a relationship between two or more sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between proteins or nucleic acid sequences as determined by the match between strings of such sequences.
  • Identity (often referred to as “similarity”) can be readily calculated by known methods, including (but not limited to) those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, NY (1994); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H.
  • each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component.
  • the transition term “comprise” or “comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts.
  • the transitional phrase “consisting of” excludes any element, step, ingredient or component not specified.
  • the transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment.
  • a material effect would cause a statistically-significant reduction in the ability of a nanocarrier to reduce the number of an unwanted cell type and/or to protect a wanted cell type in vivo.
  • the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ⁇ 20% of the stated value; ⁇ 19% of the stated value; ⁇ 18% of the stated value; ⁇ 17% of the stated value; ⁇ 16% of the stated value; ⁇ 15% of the stated value; ⁇ 14% of the stated value; ⁇ 13% of the stated value; ⁇ 12% of the stated value; ⁇ 11% of the stated value; ⁇ 10% of the stated value; ⁇ 9% of the stated value; ⁇ 8% of the stated value; ⁇ 7% of the stated value; ⁇ 6% of the stated value; ⁇ 5% of the stated value; ⁇ 4% of the stated value; ⁇ 3% of the stated value; ⁇ 2% of the stated value; or ⁇ 1% of the stated value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/776,661 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives Abandoned US20160145348A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/776,661 US20160145348A1 (en) 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785907P 2013-03-14 2013-03-14
PCT/US2014/029137 WO2014153114A1 (en) 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives
US14/776,661 US20160145348A1 (en) 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029137 A-371-Of-International WO2014153114A1 (en) 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/672,106 Continuation US10392446B2 (en) 2013-03-14 2017-08-08 Compositions and methods to modify cells for therapeutic objectives

Publications (1)

Publication Number Publication Date
US20160145348A1 true US20160145348A1 (en) 2016-05-26

Family

ID=51581420

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/776,661 Abandoned US20160145348A1 (en) 2013-03-14 2014-03-14 Compositions and methods to modify cells for therapeutic objectives
US15/672,106 Active US10392446B2 (en) 2013-03-14 2017-08-08 Compositions and methods to modify cells for therapeutic objectives
US16/510,646 Abandoned US20190330373A1 (en) 2013-03-14 2019-07-12 Compositions and methods to modify cells for therapeutic objectives
US19/064,348 Pending US20250188191A1 (en) 2013-03-14 2025-02-26 Compositions and methods to modify cells for therapeutic objectives

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/672,106 Active US10392446B2 (en) 2013-03-14 2017-08-08 Compositions and methods to modify cells for therapeutic objectives
US16/510,646 Abandoned US20190330373A1 (en) 2013-03-14 2019-07-12 Compositions and methods to modify cells for therapeutic objectives
US19/064,348 Pending US20250188191A1 (en) 2013-03-14 2025-02-26 Compositions and methods to modify cells for therapeutic objectives

Country Status (3)

Country Link
US (4) US20160145348A1 (de)
EP (1) EP2970985A1 (de)
WO (1) WO2014153114A1 (de)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085734A1 (en) * 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
US20190070277A1 (en) * 2015-05-20 2019-03-07 Kim Leslie O'Neill Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors
WO2019131770A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 核酸含有脂質ナノ粒子及びその用途
WO2019145796A2 (en) 2018-01-17 2019-08-01 Aratinga Bio Tnp Polymer-encapsulated viral vectors for genetic therapy
US10392446B2 (en) 2013-03-14 2019-08-27 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
WO2020080475A1 (ja) 2018-10-18 2020-04-23 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
WO2020092631A1 (en) * 2018-10-31 2020-05-07 Fred Hutchinson Cancer Research Center Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
WO2020234871A1 (en) * 2019-05-20 2020-11-26 Technion Research & Development Foundation Limited Metabolite encapsulating nanoparticles to enhance cellular cancer immunotherapy
JP2021016371A (ja) * 2019-07-23 2021-02-15 株式会社東芝 Ｃａｒ−ｔ細胞の製造方法、核酸導入キャリア及びキット
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
WO2021053400A2 (en) 2019-09-21 2021-03-25 Aratinga.Bio Tnp Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
US10982210B2 (en) * 2018-03-02 2021-04-20 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
WO2021234455A2 (en) 2020-05-19 2021-11-25 Ixaka France Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells
CN114286692A (zh) * 2019-06-12 2022-04-05 小利兰·斯坦福大学托管委员会 治疗病毒性感染的方法
WO2022081702A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of cd4+-t cells for mrna therapeutics
WO2022081699A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of t cells for mrna therapeutics
WO2022081694A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of fibrosis by anti-cd5-targeted fap-car t mrna-lnp
US20220127329A1 (en) * 2019-03-13 2022-04-28 Obshchestvo S Ogranichennoj Otvetstvennostyu "Anabion" Alternative intracellular signalling domain of a chimeric antigen receptor
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
US11357865B2 (en) 2020-04-27 2022-06-14 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
AU2018254263B2 (en) * 2017-04-19 2022-07-14 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
US20220249552A1 (en) * 2015-02-19 2022-08-11 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2022241131A1 (en) * 2021-05-14 2022-11-17 Medicametrix, Inc. Compositions and methods of reprogramming t cells to treat disease
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US20230174614A1 (en) * 2020-04-30 2023-06-08 Terry J FRY Multispecific anti-flt3 chimeric antigen receptors
US20230190796A1 (en) * 2017-04-07 2023-06-22 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11944680B2 (en) 2020-11-04 2024-04-02 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US12024719B2 (en) 2017-05-17 2024-07-02 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US12030938B2 (en) 2021-03-17 2024-07-09 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024210160A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited Conjugation complex
WO2024222859A1 (zh) * 2023-04-28 2024-10-31 深圳深信生物科技有限公司 经修饰的递送载体及其应用
US12252545B2 (en) 2019-12-11 2025-03-18 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
US12319925B2 (en) 2021-05-11 2025-06-03 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
US12576131B2 (en) 2018-01-18 2026-03-17 Fred Hutchinson Cancer Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3245288A1 (de) 2015-01-12 2017-11-22 Pieris Pharmaceuticals GmbH Manipulierte t-zellen und verwendungen davon
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (de) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3288569A4 (de) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modifizierte hämatopoietische stamm-/vorläuferzellen und non-t effektorzellen sowie verwendungen davon
EP4667492A3 (de) 2015-05-26 2026-04-15 Ramot at Tel-Aviv University Ltd. Gezielte lipidpartikel zur systemischen abgabe von nukleinsäuremolekülen an leukozyten
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
ES3063691T3 (en) * 2015-09-22 2026-04-20 Univ Wuerzburg J Maximilians A method for high level and stable gene transfer in lymphocytes
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP4711465A2 (de) * 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Zusammensetzungen und verfahren zur programmierung therapeutischer zellen unter verwendung gezielter nukleinsäurenanoträger
JP7062640B2 (ja) * 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN109498817B (zh) * 2017-09-14 2026-03-06 上海交通大学 一种多细胞靶向脂质体
MX2020010241A (es) 2018-03-28 2020-10-16 Cero Therapeutics Inc Composiciones de inmunoterapia celular y usos de las mismas.
EP3774906A1 (de) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimäre tim4-rezeptoren und verwendungen davon
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN110526976A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CA3110946A1 (en) * 2018-08-31 2020-03-05 Invectys SA Method to assess car functionality
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
US12514935B2 (en) * 2018-11-28 2026-01-06 Kansas State University Research Foundation Nanocarrier systems for imaging and delivery of active agents
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2020261219A1 (en) * 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
JP7630904B2 (ja) * 2019-07-23 2025-02-18 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
US20210253696A1 (en) * 2020-01-21 2021-08-19 Cero Therapeutics, Inc. Bivalent chimeric engulfment receptors and uses thereof
EP4161536A4 (de) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Neue konstrukte für chimäre antigenrezeptoren
CN111925448B (zh) * 2020-08-03 2022-06-21 山东大学 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用
EP4214513A4 (de) * 2020-09-16 2024-12-11 On Target Laboratories, LLC Nachweis von zirkulierenden tumorzellen unter verwendung von tumorgerichteten nir-mitteln
CN116322716A (zh) * 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
WO2022098797A1 (en) * 2020-11-04 2022-05-12 Fred Hutchinson Cancer Research Center Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
TW202328444A (zh) * 2021-07-26 2023-07-16 瑞士商Ｃｒｉｓｐｒ治療公司 用於製造基因工程化ｃａｒ－ｔ細胞之方法
CN113481169B (zh) * 2021-08-11 2023-06-16 南方医科大学南方医院 一种细胞激活依赖性分泌系统及应用
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
US20250177301A1 (en) * 2022-01-31 2025-06-05 Unm Rainforest Innovations Triplex nanoparticles
EP4476267A4 (de) * 2022-02-11 2026-01-07 Fred Hutchinson Cancer Center Chimäre antigenrezeptoren zur bindung von steap1
EP4676499A2 (de) * 2023-03-10 2026-01-14 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Verfahren und zusammensetzungen für die zelluläre immuntherapie-fib4

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166601A1 (en) * 1999-12-30 2003-09-04 Woodle Martin C. Novel colloid synthetic vectors for gene therapy
US20120156135A1 (en) * 2008-10-06 2012-06-21 Farokhzad Omid C Particles with multiple functionalized surface domains

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
DE602004030923D1 (de) * 2003-09-17 2011-02-17 Rodos Biotarget Gmbh Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen
WO2008011120A2 (en) * 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
EP2187971A2 (de) * 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Fold-back-diakörper-diphtherie-toxin-immunotoxin und anwendungsverfahren
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN104411331B (zh) * 2012-01-13 2018-08-21 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
EP2970985A1 (de) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Zusammensetzungen und verfahren zur modifizierung von zellen für therapeutische ziele
US20160067190A1 (en) * 2013-04-30 2016-03-10 The Children's Medical Center Corporation Injectable nano-network gels for diabetes treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166601A1 (en) * 1999-12-30 2003-09-04 Woodle Martin C. Novel colloid synthetic vectors for gene therapy
US20120156135A1 (en) * 2008-10-06 2012-06-21 Farokhzad Omid C Particles with multiple functionalized surface domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Desai et al., Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010 October ; 27(7): 247–259. *
Grandjean et al., High-level transgene expression by homologous recombination-mediated gene transfer. Nucleic Acids Research, 2011, Vol. 39, No. 15 e104, pgs. 1-15 *
Kacherovsky et al., Combination of Sleeping Beauty transposition and chemically induced dimerization selection forrobust production of engineered cells. Nucleic Acids Research, 2012, Vol. 40, No. 11 e85. pgs. 1-10 *
Stephan et al., Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. Nano Today. 2011 June 1; 6(3): 309-325. *

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392446B2 (en) 2013-03-14 2019-08-27 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11918605B1 (en) 2015-02-19 2024-03-05 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
US11918604B2 (en) 2015-02-19 2024-03-05 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
US20220249552A1 (en) * 2015-02-19 2022-08-11 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11517589B2 (en) * 2015-02-19 2022-12-06 Myeloid Therapeutics, Inc. Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
US11052138B2 (en) * 2015-05-20 2021-07-06 Thunder Biotech Inc. Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
US12076378B2 (en) 2015-05-20 2024-09-03 Kim Leslie O'Neill Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
US20190070277A1 (en) * 2015-05-20 2019-03-07 Kim Leslie O'Neill Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors
US10821162B2 (en) 2015-05-20 2020-11-03 Kim Leslie O'Neill Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
US10828355B2 (en) 2015-05-20 2020-11-10 Kim Leslie O'Neill Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US12252533B2 (en) 2015-06-24 2025-03-18 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US12030952B2 (en) 2015-10-02 2024-07-09 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US11787868B2 (en) 2015-10-02 2023-10-17 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
US12358997B1 (en) 2015-10-02 2025-07-15 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/anti-human transferrin receptor antibodies
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018085734A1 (en) * 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
JP2023171756A (ja) * 2017-01-05 2023-12-05 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
EP3565535A4 (de) * 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center Systeme und verfahren zur verbesserung der impfstoffwirksamkeit
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
JP7733703B2 (ja) 2017-01-05 2025-09-03 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
CN110121336A (zh) * 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
US20230312674A1 (en) * 2017-01-05 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
JP2020504133A (ja) * 2017-01-05 2020-02-06 フレッド ハッチンソン キャンサー リサーチ センター ワクチン効力を改善するためのシステム及び方法
US20230190796A1 (en) * 2017-04-07 2023-06-22 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
AU2018254263B2 (en) * 2017-04-19 2022-07-14 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
US12024719B2 (en) 2017-05-17 2024-07-02 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US12551561B2 (en) 2017-12-27 2026-02-17 Takeda Pharmaceutical Company Limited Nucleic acid-containing lipid nano-particle and use thereof
KR20200104360A (ko) 2017-12-27 2020-09-03 다케다 야쿠힌 고교 가부시키가이샤 핵산-함유 지질 나노-입자 및 그의 용도
KR20250131843A (ko) 2017-12-27 2025-09-03 다케다 야쿠힌 고교 가부시키가이샤 핵산-함유 지질 나노-입자 및 그의 용도
WO2019131770A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 核酸含有脂質ナノ粒子及びその用途
WO2019145796A2 (en) 2018-01-17 2019-08-01 Aratinga Bio Tnp Polymer-encapsulated viral vectors for genetic therapy
US12576131B2 (en) 2018-01-18 2026-03-17 Fred Hutchinson Cancer Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
US10982210B2 (en) * 2018-03-02 2021-04-20 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
JP7634924B2 (ja) 2018-10-18 2025-02-25 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
WO2020080475A1 (ja) 2018-10-18 2020-04-23 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
CN112912509A (zh) * 2018-10-18 2021-06-04 武田药品工业株式会社 T细胞的活化/增殖方法
JPWO2020080475A1 (ja) * 2018-10-18 2021-09-30 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
WO2020092631A1 (en) * 2018-10-31 2020-05-07 Fred Hutchinson Cancer Research Center Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
US20220127329A1 (en) * 2019-03-13 2022-04-28 Obshchestvo S Ogranichennoj Otvetstvennostyu "Anabion" Alternative intracellular signalling domain of a chimeric antigen receptor
US12540169B2 (en) * 2019-03-13 2026-02-03 Limited Liability Company «Anabion» (Llc «Anabion») Alternative intracellular signalling domain of a chimeric antigen receptor
WO2020234871A1 (en) * 2019-05-20 2020-11-26 Technion Research & Development Foundation Limited Metabolite encapsulating nanoparticles to enhance cellular cancer immunotherapy
CN114286692A (zh) * 2019-06-12 2022-04-05 小利兰·斯坦福大学托管委员会 治疗病毒性感染的方法
JP2021016371A (ja) * 2019-07-23 2021-02-15 株式会社東芝 Ｃａｒ−ｔ細胞の製造方法、核酸導入キャリア及びキット
US12398190B2 (en) 2019-07-23 2025-08-26 Kabushiki Kaisha Toshiba Method of producing CAR-T cells, nucleic acid-introducing carrier and kit
JP2023153231A (ja) * 2019-07-23 2023-10-17 株式会社東芝 Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
JP7653113B2 (ja) 2019-07-23 2025-03-28 株式会社東芝 Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
WO2021053400A2 (en) 2019-09-21 2021-03-25 Aratinga.Bio Tnp Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
US12252545B2 (en) 2019-12-11 2025-03-18 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
US12472267B2 (en) 2020-04-27 2025-11-18 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
US11357865B2 (en) 2020-04-27 2022-06-14 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
US20230174614A1 (en) * 2020-04-30 2023-06-08 Terry J FRY Multispecific anti-flt3 chimeric antigen receptors
WO2021234455A3 (en) * 2020-05-19 2022-02-24 Ixaka France Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells
WO2021234455A2 (en) 2020-05-19 2021-11-25 Ixaka France Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells
WO2022081699A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of t cells for mrna therapeutics
WO2022081702A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of cd4+-t cells for mrna therapeutics
US20230233706A1 (en) * 2020-10-13 2023-07-27 The Trustees Of The University Of Pennsylvania In vivo targeting of CD4+-T cells for mRNA therapeutics
JP2023546067A (ja) * 2020-10-13 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ｍＲＮＡ治療剤のためのＴ細胞のインビボ標的化
CN117042780A (zh) * 2020-10-13 2023-11-10 宾夕法尼亚大学理事会 用于mRNA治疗剂的T细胞的体内靶向
WO2022081694A1 (en) * 2020-10-13 2022-04-21 The Trustees Of The University Of Pennsylvania In vivo targeting of fibrosis by anti-cd5-targeted fap-car t mrna-lnp
EP4228601A4 (de) * 2020-10-13 2025-08-06 Univ Pennsylvania In-vivo-targeting von fibrose durch anti-cd5-gerichtete fap-car-t-mrna-lnp
US11944680B2 (en) 2020-11-04 2024-04-02 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US12030938B2 (en) 2021-03-17 2024-07-09 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US12319925B2 (en) 2021-05-11 2025-06-03 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2022241131A1 (en) * 2021-05-14 2022-11-17 Medicametrix, Inc. Compositions and methods of reprogramming t cells to treat disease
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024210160A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited Conjugation complex
WO2024222859A1 (zh) * 2023-04-28 2024-10-31 深圳深信生物科技有限公司 经修饰的递送载体及其应用
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Also Published As

Publication number Publication date
US20180030153A1 (en) 2018-02-01
US10392446B2 (en) 2019-08-27
US20250188191A1 (en) 2025-06-12
EP2970985A1 (de) 2016-01-20
WO2014153114A1 (en) 2014-09-25
US20190330373A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US20250188191A1 (en) Compositions and methods to modify cells for therapeutic objectives
US20240285797A1 (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarrier
AU2019262059B2 (en) Nanoparticles for gene expression and uses thereof
US11872195B2 (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CA3162629A1 (en) Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
Tang et al. Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination
HK40082343B (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
HK40082343A (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
AU2022249392A1 (en) Materials and methods for generating antigen-specific t cells and treating diseases
NZ787266A (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
HK40000391B (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
HK40000391A (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers

Legal Events

Date Code Title Description
AS Assignment

Owner name: FRED HUTCHINSON CANCER RESEARCH CENTER, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STEPHAN, MATTHIAS;REEL/FRAME:037875/0090

Effective date: 20160229

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION